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The aim of this dissertation was to describe the two most commonly encountered 
discordant rifampicin (RIF) susceptibility results encountered in the routine National 
Tuberculosis Control Programme (NTBCP) testing algorithm of South Africa. Part 1 of the 
study focuses on discordant RIF resistant (RIFR) result by Xpert MTBB/RIF (Xpert) and 
RIF susceptible (RIFS) result by line probe assay (LPA) and determines which result is 
the true result as determined by sequencing. Part 2 of the study focuses on RIFR isolates 
with miscellaneous rpoB mutations detected by LPA and to determine the minimum 
inhibitory concentration (MIC) level of isolates with these specific mutations when routine 
liquid drug susceptibility testing is expected to miss resistance.  
The MSc candidate performed DNA extractions for purposes of the study for LPA and 
rpoB PCR. The MSc candidate performed and interpreted the following assays; repeat 
LPA, rpoB PCR and MIC. PCR products of rpoB PCR were sent to Inqaba Biotechnical 
Industries (Pretoria, South Africa) for Sanger sequencing and sequencing results were 
sent back to the MSc candidate and the MSc candidate interpreted sequencing results. 










Background: The Xpert MTB/RIF assay was adopted as the initial diagnostic test for patients with 
presumptive tuberculosis (TB) by the South African National TB Control programme in December 2010. 
Rifampicin (RIF) resistance detected by the Xpert MTB/RIF (Xpert) is confirmed by a line probe assay (LPA) 
(GenoType MTBDRplus) and/or phenotypic (culture-based) drug susceptibility testing (DST) by MGIT 
(Mycobacterial Growth Indicator Tube) on the culture isolate from a 2nd specimen. 
Although both the Xpert and LPA target the rifampicin resistance determining region (RRDR) of the rpoB 
gene, discordant RIF results (Xpert RIF resistant (RIFR), LPA RIF susceptible (RIFS)) have been reported. In 
addition, in cases where genotypic tests detect an rpoB mutation, inferring RIF resistance, routine 
phenotypic DST may report a RIF susceptible result. This is usually due to disputed rpoB mutations.  
Aim: The aims of this study are to determine 1) whether the discordance between Xpert and LPA is due 
to false RIFR by Xpert or false RIFS by LPA and to elucidate the causes of false results and 2) the frequency 
and types of rpoB mutations expected to test susceptible on routine phenotypic DST and their 
corresponding RIF MIC (minimum inhibitory concentration). 
Methods: Consecutive isolates with discordant Xpert RIFR and LPA RIFS results were selected during 
routine review. For the Xpert, parameters including bacterial DNA load and cycle threshold (Ct) of the 
probes were evaluated. In addition, isolates with a pattern of any absent rpoB WT band and absent MUT 
band on the LPA strip (“miscellaneous rpoB mutations”) were selected for MIC testing using the MGIT 960 
system and EpiCenter TB eXiST software. Sanger sequencing of the rpoB gene from codon 462 to 591 was 
performed on all selected isolates. 
Results and discussion: Discordant Xpert/LPA results: From the total of 1542 patients with RIFR results by 
Xpert, 106 (6.9%) had a discordant LPA RIFS result. Sequencing results were available for 101 isolates of 
which 78 (77.2%) had no rpoB mutation detected and these were categorized as false RIFR by Xpert. 
Mutations were detected by sequencing in the remaining 23 (22.8%); these were categorized as false RIFS 
by LPA. Probe delay occurred in 56/76 (73.7%) cases compared with 104/1436 (7.2%) controls (p <0.0001). 
Probe delay with ∆Ct max value between 4.1 and 4.9 and is also a significant predictor of false RIFR by 
Xpert (p value <0.001). Double probe delay was observed only in the false RIFR by Xpert group and occurred 
in 12/76 (15.8 %) with p value <0.001. “Very Low” bacterial load occurred in 47/76 (61.8%) cases compared 
with 192/1436 (13.4%) controls (p <0.0001) and is a significant predictor of false RIFR by Xpert. A RIFR 
result by Xpert that is determined by probe delay where the Ct max is >4 and there is a Very Low bacterial 
load has a positive predictive value (PPV) of 64.2 % of being false and where the Ct max is between 4.1 
and 4.9 with Very Low bacterial load, the PPV of a false result increases to 85.7%.  For the false RIFS results 
by LPA, the majority 11/23 (47.8%) were due to technical errors. In 6/23 (26.1%) it was due to mixed 
infection and in 2/23 (8.7%) there was laboratory mix up. In the remaining 4/23 (17.4%) the cause could 
not be determined and mixed infection or a laboratory mix up could not be excluded. 
Discordant genotypic/phenotypic results: RIF resistance was detected in 1502 patients by LPA, of which 
169 (11.3%) had a miscellaneous mutation. In addition, a further 21 isolates were selected from “Part 1” 
of the study, where sequencing confirmed that the rpoB mutation was not one of the high level / high 
confidence rpoB mutations. A total of 178 isolates had both MIC and rpoB sequencing results. In our study 
140/178 (78.7%) isolates with miscellaneous rpoB mutations (n=158) or previously described disputed 
rpoB mutations (n=20) had MIC values ranging from ≤0.0625 µg/ml to 1.0 µg/ml. An MIC >1.0 µg/m was 
determined for 38/178 (21.3%) that would have tested RIFR by MGIT DST. 
Conclusion: Arising from this study is a laboratory based guideline that is now used within NHLS TB 
laboratories detailing steps on how to detect possible false RIFR results by Xpert MTB/RIF and on how to 
troubleshoot discordant Xpert RIFR and LPA RIFS results. A database has been created from the results 
obtained in this study that lists specific rpoB mutations and their corresponding MIC value and has the 
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GLOSSARY OF TERMS 
 
Borderline RIF resistance is defined as a discrepancy between liquid and solid culture 
based DST methods, with the liquid-based phenotypic DST method reporting RIFS but 
the solid method phenotypic DST reporting RIFR and genotypic testing (either or both of 
Xpert and LPA and / or rpoB sequencing) detects an rpoB mutation and the MIC is >0.5 
and ≤1.0 µg/ml (Van Deun et al., 2013). 
Clonal heterogeneity is clonal diversity with different MIRU-VNTR patterns due to one 
clone of MTB that has evolved over a shorter period of time from susceptible to resistant 
(Cohen et al., 2012). 
Delta Ct max (Ct max) is defined as the difference between the Ct values of the latest 
and earliest probes of Xpert MTB/RIF (Lawn and Nicol, 2011).  
Delta Ct min (Ct min) is the smallest Ct difference between any pair of probes (Xpert 
MTB/RIF) (Lawn and Nicol, 2011). 
Disputed rpoB mutation is an rpoB mutation that is phenotypically RIFS with routinely 
used liquid based methods and thus give discordant genotypic / phenotypic rifampicin 
results (Van Deun et al., 2013). 
a. There is a RIF susceptible MGIT result OR 
b. The MIC result is either susceptible (<0.0625ug/mml) or low-level RIF 
resistant (> 0.0625 and <=1g/ml) 
False RIFS result by LPA: Rifampicin resistance was reported by Xpert, but LPA reported 
a RIF susceptible result. There was a mutation detected in the RRDR of the rpoB gene 
by sequencing. 
False RIFR result by Xpert: Rifampicin resistance was reported by Xpert, but LPA 
reported RIF susceptible. There was no mutation detected in the RRDR of rpoB gene by 
rpoB sequencing. 
Heteroresistance is defined as the presence of both susceptible and resistant bacteria 





A high level / high confidence rpoB mutation is one of the following mutations:  S531L 
/ H526Y / H526D / D516V 
a. It is clearly identified by the LPA as the following rpoB band patterns: [[WT8 
absent and MUT3 present]; [WT7 absent and MUT 2A present]; [WT7 
absent and MUT2B present] and [WT3&4 absent and MUT 1 present] 
respectively 
b. The expected MIC would be high level (>32ug/ml) (Van Deun et al., 2013) 
c.  The MGIT RIF result is always resistant (concordant LPA and MGIT results 
= R) 
Low level RIF resistance occurs when both liquid and solid media phenotypic DST 
results show susceptibility to RIF at the routine critical concentration recommended for 
each method (no discrepancy between the two phenotypic methods) but the genotypic 
test (either or both of Xpert and LPA and / or rpoB sequencing) detects an rpoB mutation 
and the MIC is >0.0625 and ≤0.5 µg/ml and the MGIT DST result would be expected to 
be RIF susceptible (Van Deun et al., 2013). 
Miscellaneous rpoB mutations are all rpoB mutation in the RIF resistance determining 
region (RRDR) that are detected by the LPA except the high level / high confidence rpoB 
mutations. It is identified by the LPA pattern of an (any) [absent WT band and absent 
MUT bands]. At the time of selection of isolates for this study, the MIC, MGIT result and 
actual rpoB mutation (that would be determined by sequencing), are not known. 
Mixed infection is the presence of different clones of MTB with different MIRU-VNTR 
patterns at two or more loci in the same specimen occurring as a result of multiple 
infections (Cohen et al., 2012). 
Probe delay is an Xpert analysis where MTB is detected and one or more probes have 
delayed onset of fluorescence with delta Ct max value of >4 (Lawn and Nicol, 2011).  
Probe dropout is an Xpert analysis where MTB is detected and one or more probes have 







Susceptible rpoB mutation 
a. A miscellaneous / disputed rpoB mutation where there is an MIC result 
available for it and the MIC is ≤0.0625ug/ml (Gumbo, 2010) 
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1. Literature review 
 
1.1 Introduction 
Tuberculosis, caused by Mycobacterium tuberculosis (MTB), is the greatest killer 
due to a single infectious agent worldwide (WHO, 2016). In 2015, MTB was 
responsible for approximately 1.8 million deaths (WHO, 2016). Over 95% of 
tuberculosis (TB) deaths occur in low- and middle-income countries. Multidrug-
resistant TB (MDR-TB) is defined as MTB that is resistant to at least both of the 
first-line anti-TB drugs isoniazid (INH) and rifampicin (RIF). It poses a serious 
challenge for global TB control and makes successful treatment difficult. In 2015, 
there were an estimated 480 000 people who developed MDR-TB worldwide 
(WHO, 2016). 
In South Africa, the same is true that TB is the greatest infectious killer and South 
Africa was among the six countries that had the largest number of incident cases 
in 2015 (WHO, 2016). There were 450,000 new cases of active TB reported in 
South Africa in 2015, equating to 1% of the total South African population and  
South Africa had the second highest absolute number of notified RIF-resistant 
(RR)/MDR cases globally with 18 734  (WHO, 2016). 
Globally, in 2015, approximately 3.9% of new TB cases were MDR-TB and 21% 
of previously treated cases were MDR-TB (WHO, 2016). In South Africa, 2.1% of 
new cases and 4.3% of retreatment cases were MDR-TB (WHO, 2016). In 2014 
South Africa ranked tenth (amounting to 2.1% of the total global burden) among 
the 27 high burden MDR-TB countries (WHO, 2015). 
Lack of access to early diagnosis of drug resistant TB is one of the major 
obstacles toward the correct management and control of drug resistant TB. The 
development of commercially available rapid molecular tests that are applicable 
in high TB prevalence low-income settings, show great promise in meeting this 





(LPA) (Hain Lifescience, Nehren, Germany) and the Xpert MTB/RIF (Xpert) 
(Cepheid, Sunnyvale, USA). The LPA and Xpert assays are genotypic assays that 
detect mutations in the MTB genome conferring RIF (and isoniazid (INH) in the 
case of the LPA) resistance. Xpert detects MTB in specimens in less than one 
day (usually 3-4 hours) and the LPA (if performed directly on smear positive 
specimens or on a cultured isolate of MTB) also has a short turnaround time of 
24-48 hours. In addition, they both have a high sensitivity for the detection of RIF 
resistance (Xpert [pooled estimate] 95% (Steingart et al., 2014) and LPA [pooled 
estimate] 98%) (Morgan et al., 2005)). In 2008, the World Health Organization 
(WHO) endorsed the use of the LPA for the detection of drug resistant TB in areas 
with a high prevalence of HIV and MDR-TB (WHO, 2010b). In 2010, the WHO 
recommended Xpert for both the diagnosis of TB and the rapid detection of RIF 
resistance (WHO, 2010c, Boehme et al., 2010). Both LPA and Xpert were 
evaluated in comparison with culture based (phenotypic) drug susceptibility 
testing methods. 
Rifampicin, first introduced in 1972, is a key drug in the four-drug treatment 
regimen of tuberculosis. RIF has early bactericidal effects on metabolically active 
MTB. It also has excellent sterilizing activity against semi-dormant (i.e. slow or 
non-growing) MTB (Somoskovi et al., 2001, Almeida Da Silva and Palomino, 
2011). The introduction of RIF to combined therapy reduced the duration of TB 
treatment from 18 months to a short course of six months (Grosset, 1978, 
Mitchison, 1992, Somoskovi et al., 2001). RIF-resistance is a key determinant for 
treatment failure (Lew et al., 2008, Ahmad and Mokaddas, 2014). Detection of 
RIF-resistance is regarded as a surrogate for the detection of MDR-TB, since the 
prevalence of RIF mono-resistance is generally considered to be low (Lawn and 
Nicol, 2011, Somoskovi et al., 2001). 
RIF inhibits mycobacterial transcription by binding to the β-subunit of bacterial 
deoxyribonucleic acid (DNA) dependent ribonucleic acid (RNA) polymerase 
(Telenti et al., 1993, Ramaswamy and Musser, 1998).The important catalytic 
region of RNA polymerase of bacteria has a molecular mass of 400kDa and is 





Archambault and Friesen, 1993). Mutations that confer RIF resistance almost 
entirely occur in the RIF Resistance Determining Region (RRDR) of the rpoB gene 
of organisms such as Escherichia coli (Ezekiel and Hutchins, 1968) and MTB 
(Ramaswamy and Musser, 1998). The RRDR is 81 base pairs long comprising 27 
codons (from codon 507 to 533 using the Escherichia coli numbering scheme). 
More than 95% of RIF resistant (RIFR) MTB strains contain a mutation, either a 
single nucleotide polymorphism (SNP) or a deletion, of a nucleotide in the RRDR 
(Somoskovi et al., 2001, Telenti et al., 1993, Ramaswamy and Musser, 1998). A 
SNP is a change in a single nucleotide from the wild-type nucleotide at that 
position. 
 
1.2 Drug resistance in Mycobacterium tuberculosis 
Members of the MTB complex (including Mycobacterium tuberculosis, 
Mycobacterium africanum and Mycobacterium bovis among others) as well as the 
non-tuberculous mycobacteria (NTM) are naturally resistant to many commonly 
used antibiotics due to the slow uptake of drugs across the hydrophobic lipid-rich 
cell wall (Viveiros et al., 2003). Mycobacterium bovis and Mycobacterium canettii 
are naturally resistant to pyrazinamide (PZA) (Ramaswamy and Musser, 1998). 
Acquired TB-drug resistance in previously susceptible MTB occurs wherever anti-
TB drugs are used for the treatment of TB. Factors that contribute to the 
emergence of MTB drug resistance include diagnostic delay (leading to high 
bacterial burden), ineffective treatment (due to drug shortages, inappropriate 
regimens and treatment interruption), pharmacokinetic variability and possibly 
patients with underlying immune suppression (Barnes, 1987, Gordin et al., 1996, 
Reichman, 1997). 
With increasing anti-TB drug use and misuse, drug resistant MTB isolates have 
emerged through the selection of pre-existing drug resistant mutants. TB drug 
resistance is an amplification of a natural phenomenon (Palomino and Martin, 





(Zainuddin and Dale, 1990) on plasmids or transposons, but through 
chromosomal mutations that occur spontaneously during bacterial multiplication. 
The drug resistant MTB mutants that arise spontaneously are subsequently 
selected during inappropriate anti-TB treatment (e.g. monotherapy) resulting in a 
predominant mutant MTB population. Thus, most MTB drug resistance is a result 
of specific mutations in target genes. Gene alterations that change the structure 
of the target protein but do not compromise the protein’s function allow the mutant 
strain to be selected in the presence of the drug. The most common mechanism 
of MTB resistance in general is due to SNP; other mechanisms include drug efflux 
(Louw et al., 2009). 
 
1.3 Rates of spontaneous mutations giving rise to INH & RIF resistance in 
Mycobacterium tuberculosis  
Mutations in the rpoB gene alter the amino acid sequence of RNA polymerase in 
such a way that RIF cannot bind to the enzyme and thus will not inhibit its function. 
Spontaneous mutations in the rpoB gene that cause resistance to RIF occur very 
rarely, at an average of 1 in 100 million cells. This means that the chance of 1 
mutation occurring in the RRDR of the rpoB gene is approximately once every 
time 100 million bacilli divide in a drug free environment (Grange, 1990). Genetic 
mutations resulting in resistance to INH occur more frequently or at a rate of 
approximately 10-7 per cell division (Grange, 1990). More than 107 bacilli may be 
present per lesion in lung cavities (Canetti, 1965). Therefore, if INH is used as a 
mono-therapy for a patient with cavitary TB, there will be a strong likelihood of 
there being at least one bacillus with INH resistance within the cavity that may be 
selected out during INH mono-therapy (Almeida Da Silva and Palomino, 2011). 
The occurrence of MDR TB due to spontaneous mutations occurring for both RIF 
and INH simultaneously is extremely rare; no single gene mutation associated 
with MDR TB exists and mutations resulting in resistance to different drugs arise 
independently. By using INH and RIF the probability that any single bacillus in a 





(10-7x10-8) (Iseman and Madsen, 1989, Grange, 1990). This is the main reason 
that a multidrug regimen is used in anti-TB treatment (Cohn et al., 1959, Gillespie, 
2007, Almeida Da Silva and Palomino, 2011). 
 
1.4 Molecular mechanism of rifampicin resistance 
Within the RRDR, the most common rpoB mutations causing RIF resistance in 
MTB worldwide are S531L, H526D, H526Y and D516V. These mutations account 
for 75-85% of rpoB mutations causing RIF resistance (Somoskovi et al., 2001, 
Huitric et al., 2006, Rigouts et al., 2007). These four rpoB mutations almost always 
give rise to high-level RIF resistance (minimum inhibitory concentration (MIC) 
above 16 µg/ml) (Ohno et al., 1996, Somoskovi et al., 2001, Huitric et al., 2006, 
Cavusoglu et al., 2006). When performing conventional phenotypic drug 
susceptibility testing (DST) with liquid culture-based methods such as the 
Mycobacterial Growth Indicator Tube (MGIT; Becton Dickinson, MD), these 
particular “high level” rpoB mutations would typically give concordant RIFR results 
(both MGIT and the genotypic method would give a RIFR result). These high level 
rpoB mutations have also been termed “non-disputed” or “high confidence” rpoB 
mutations. 
The remaining 15-25% “less common” rpoB mutations are associated with 
variable RIF MICs (Huitric et al., 2006, Ohno et al., 1996) and may not be detected 
by conventional liquid-based phenotypic DST methods such as MGIT, which uses 
the critical concentration of 1µg/ml RIF. The rpoB mutations have been termed 
“disputed rpoB mutations” if they test phenotypically susceptible with routinely 
used liquid based methods and they thus lead to discordant genotypic / 
phenotypic rifampicin results. Some are termed “low level” RIF resistance 
mutations when MIC testing reveals MICs <1 µg/ml but >0.0625 µg/ml. The 
clinical significance of the disputed rpoB mutations is not entirely clear but there 
is some information that indicates that the majority of patients infected with MTB 





standard (drug susceptible) TB regimens (Ohno et al., 1996, Williamson et al., 
2012, Van Deun et al., 2013). 
Less commonly, RIF resistance may arise from mutations in the rpoB gene that 
occur either upstream or downstream of the RRDR (Somoskovi et al., 2001). 
These too may lead to either high or low-level RIF resistance (Siu et al., 2011). 
 
1.5 Diagnostic test methods commonly used for detecting rifampicin 
resistance in Mycobacterium tuberculosis and their limitations 
Principles of and methods for drug susceptibility testing 
Drug susceptibility testing (DST) is used to determine whether a particular 
organism is susceptible or resistant to the drugs used in therapy. A patient 
infected with a susceptible organism has a greater probability of treatment 
success if that drug is used as treatment (Isenberg, 1988, Leekha et al., 2011). A 
patient infected with a resistant strain has a high probability of failing treatment if 
that drug is used (Isenberg, 1988). Standardised and reliable methods to ensure 
accurate and reproducible results are required to provide guidance for the 
treatment of each patient. A false resistant or false susceptible result may lead to 
a clinician replacing an effective regimen with a less effective one. This in turn will 
have an impact not only on the patient’s health, but also result in an increased 
expenditure for the healthcare system and may also result in the spread of drug-
resistant strains in the community (Pinto and Menzies, 2011). 
Drug susceptibility of MTB may be determined phenotypically by observing growth 
or metabolic inhibition of the MTB organisms in a medium with an anti-TB drug. It 
may also be performed genotypically by detecting known mutations in genes that 
confer resistance to anti-TB drugs. 
 
1.5.1 Phenotypic DST methods 
Phenotypic (“culture-based”) TB drug susceptibility testing is considered to be 





diagnosing drug-resistant TB. Phenotypic DST will detect most mechanisms of 
resistance including those for which no mutation causes is known to cause the 
resistance.  Phenotypic susceptibility testing methods are the most widely used 
methods and classify MTB isolates into drug-resistant or drug-susceptible, based 
on their ability to grow in the presence of a “critical concentration” of the test drug. 
This critical concentration is defined as the lowest concentration of a drug that will 
inhibit ≥95% of wild type (WT) strains of MTB that have never been exposed to 
the drug and that does not inhibit resistant strains isolated from patients not 
responding to the drug (Canetti et al., 1963). The critical concentration is an 
epidemiological cut-off used to differentiate between WT (susceptible) and non-
WT (resistant) strains (Canetti et al., 1963, Bottger, 2011) rather than a clinical 
breakpoint used to predict clinical efficacy (Kim, 2005). The MIC is defined as the 
minimum concentration of drug required to inhibit a visible growth of more than 
99% of MTB population (Angeby et al., 2012). 
It was observed that WT strains of MTB that have never been exposed to RIF do 
not exhibit great variation in MIC to RIF (Canetti et al., 1963, Angeby et al., 2012). 
Since drug resistance occurs due to the selection of pre-existing mutants, both 
drug resistant mutants and drug susceptible wild types are likely to be present in 
any large population of MTB bacilli in a culture medium. Resistance was deemed 
clinically significant when at least 1% of the population of bacilli grew at the critical 
concentration. A smaller proportion of mutant organisms was not thought to have 
clinical significance (Canetti et al., 1963). 
A comparison of laboratory findings and clinical outcomes revealed that an 
increase in mutant cells in a population and growth of >1% of the population at 
the critical concentration of drug could predict therapeutic failure. Resistant cells 
below 1% were typically successfully controlled with standard anti-TB treatment 
(Canetti et al., 1963). 
Recent studies have criticized the use of a single critical concentration for MTB 
DST, suggesting that determining the specific MIC of each isolate, as is widely 





Phenotypic DST may be performed directly from specimens or indirectly from 
cultured isolates. 
Direct phenotypic DST is performed from a decontaminated specimen or 
untreated specimen (the latter only if the specimen is from a normally sterile site) 
that is TB microscopy-smear-positive with acid alcohol fast bacilli (AFB). The 
specimen is inoculated directly onto drug-containing media and drug-free control 
media. The advantages of direct DST are that it has a reduced turnaround time 
compared with indirect DST, and the DST is more representative of the MTB 
complex population in the original sample. The disadvantages are that the method 
can only be performed on a smear-positive specimen and it could result in 
increased expenditure where there is high incidence of smear-positive specimens 
containing NTM (O'Grady et al., 2011, WHO, 2010a). 
Indirect phenotypic DST involves isolation of pure growth of MTB from clinical 
specimens in culture media followed by inoculation of the isolate into a drug 
containing medium. 
Phenotypic DST methods for MTB include the absolute concentration method, the 
resistance ratio method and the 1% proportion method (Canetti et al., 1963). The 
former two are used less often as they are labour intensive. The WHO 
recommends that laboratories performing phenotypic DST perform the proportion 
method, which can be performed either directly or indirectly Worldwide, the 
proportion method is the preferred method among the conventional methods and 
is considered the gold standard (Kim, 2005). Drug susceptibility results for the 
above three methods do not differ significantly for RIF and INH (WHO, 2010a). 
Indirect DST methods depend on the primary culture becoming positive for MTB. 
Once performed, DST results may take from two to six weeks; the total process 
could therefore take one to three months. This delay has a great impact in patients 
who may suffer clinical deterioration during inadequate therapy and patients who 
may continue to transmit drug-resistant TB into the community. Therefore, there 






1.5.1.1 Proportion drug susceptibility testing methods 
Conventional phenotypic DST by the proportion method can be performed using 
either solid media such as agar or egg-based media (e.g., Löwenstein–Jensen 
(LJ) media enriched with glycerol and asparagine) or liquid media that contains 
serum or bovine albumin (e.g. MGIT) (Kim, 2005). 
1.5.1.1.1 Solid media based proportion method 
The solid agar proportion method depends on the critical concentration of the drug 
and the critical proportion of resistant bacilli in a population. It involves comparing 
the number of colony forming units that grow in the drug-containing media to that 
in the drug-free media (Canetti et al., 1963). 
The number of colonies obtained from the control drug-free media indicates the 
number of viable bacilli contained in the corresponding dilution. The number of 
colonies obtained from the drug-containing media indicates the number of 
resistant bacilli in the inoculum dilution. The ratio between the number of colonies 
from the drug-containing media and the number of colonies from the control media 
is used to show whether the strain is susceptible or resistant. If the ratio is below 
the critical proportion (1%) then the isolate is reported susceptible and if the result 
is above the critical proportion then the isolate is reported resistant. The control 
media should have at least 20 countable colonies for the DST to be interpreted 
unless the isolate is resistant (Canetti et al., 1963, Canetti et al., 1969). The RIF 
critical concentration using LJ media is 40 µg/ml (Canetti et al., 1963, Canetti et 
al., 1969). 
Technical errors could cause false susceptibility results that may lead to 
discordance with a genotypic test that detects resistance. Therefore, it is 
important that the inoculum is prepared correctly; if the inoculum is too small, the 
sample size will not be enough to detect the resistant mutant’s critical proportion 
leading to false susceptible results. If the inoculum is too large the spontaneously 
occurring mutants may be present in a large enough amount to give a false 
resistant result. Contamination with NTM can also lead to a false resistant result 





1.5.1.1.2 Liquid media based proportion method  
Various liquid media based DST methods have been used to provide 
susceptibility results as they have a more rapid turn-around time than DST on 
solid media (WHO, 2007). Early liquid media based DST methods include the 
BACTEC 460 system (Becton Dickinson Diagnostic Systems, Sparks, MD) which 
provides faster susceptibility results (Siddiqi et al., 1981, Roberts et al., 1983). 
However, the requirement for radioactive waste disposal makes it unsafe, difficult 
and expensive (Siddiqi et al., 2012). The BACTEC 460 system has since been 
replaced by the non-radiometric BACTEC MGIT 960 system (Becton Dickinson 
Diagnostic Systems, Sparks, MD) which was endorsed by the WHO in 2007 
(WHO, 2007). Other liquid DST methods include non-commercial microscopic 
observation of drug susceptibility (MODS), nitrate reductase assay in liquid 
medium (NRA) and commercially available systems like the Trek Sensititre 
MYCOTB MIC plate (Treck Diagnostic Systems, Cleveland, OH). 
Mycobacterial Growth Indicator Tube (MGIT) 
The BACTEC MGIT (Mycobacterial Growth Indicator Tube) manual and 
automated systems are commercial test methods based on liquid media originally 
introduced for the rapid detection of mycobacterial growth (primary culture of 
MTB). The BACTEC MGIT 960 SIRE kit (Becton Dickinson, Franklin Lakes, New 
Jersey, USA) is an indirect qualitative DST method for the detection of “first-line” 
drug resistance to anti-TB drugs, namely streptomycin (STR), INH, RIF, and 
ethambutol (EMB). It takes 4 to 13 days to obtain a DST result after the MGIT 
culture is positive for MTB. This test was developed with critical concentrations 
for STR (1 µg/ml), INH (0.1 µg/ml), RIF (1 µg/ml) and EMB (5 µg/ml) (Rusch-
Gerdes et al., 1999, Siddiqi SH, 2006). 
There is a fluorescent compound quenched by oxygen at the bottom of the culture 
medium MGIT tube; once oxygen is consumed by actively growing 
microorganisms, the compound fluoresces and is detected by the BACTEC MGIT 
960 instrument. The DST is based on the method in which the growth of MTB 





tube. The BACTEC MGIT 960 instrument continuously analyses fluorescence of 
the drug-containing tube compared to that of the drug-free control tube. 
Routine RIF susceptibility testing in MGIT is performed at a critical concentration 
of 1 µg/ml and MIC testing at various drug concentrations can be performed with 
the aid of EpiCenter TB eXiST software (Becton Dickinson, Heidelberg, 
Germany). The MGIT 960 only allows a maximum of 13 days incubation period 
for the growth control tube to reach the required growth unit (GU>400) for 
interpretation. If the required growth unit is not reached within the 13 days of 
incubation, an invalid result is obtained. The EpiCenter TB eXiST software is 
useful as it allows the MGIT system to incubate slower growing MTB strains for 
longer, thus susceptibility results can be obtained after a longer incubation period 
(i.e. up to 42 days). The Epicenter System has been used to determine the RIF 
MICs of MTB isolates with various rpoB mutations for RIF (Springer et al., 2009, 
Sirgel et al., 2013). 
Limitations of traditional (non-EpiCenter) MGIT DST include failing to obtain a 
valid RIF susceptibility result for a slow growing MTB isolate. The limited 
incubation time when using routine MGIT DST may also fail to detect some slow 
growing MTB isolates that harbour particular rpoB mutations that have been 
associated with possible loss of fitness (Rigouts et al., 2013). Errors or discordant 
RIF susceptibility results may also arise for liquid based DST if the inoculum is 
not prepared correctly. 
The critical concentration of 1 µg/ml used in routine MGIT DST for RIF has been 
criticised as being too high. For certain rpoB mutations, the MGIT result is 
reported as susceptible, causing a discordant overall result between the genotypic 
and the liquid based phenotypic tests. Solid media (LJ)-based phenotypic testing 
correctly identifies these MTB isolates as RIFR (Van Deun et al., 2009, Van Deun 







1.5.2 Genotypic drug susceptibility testing 
Molecular or genotypic DST depends on the detection of mutations that confer 
drug resistance. If a mutation is detected and known to be associated with 
resistance, the MTB is reported to be drug resistant whereas if no mutation is 
detected the MTB is reported as susceptible (i.e. wild type). Mutations associated 
with resistance to many of the anti-TB drugs have been described (Zhang and 
Young, 1994, Telenti, 1998, Johnson et al., 2006, Almeida Da Silva and Palomino, 
2011). Genotypic methods can be categorized into two groups: probe based 
methods and sequence based methods. 
1.5.2.1 Line probe assays (LPA) 
Two LPA assays; the GenoType MTBDRplus (Hain Lifescience, Nehren, 
Germany) and the INNO LiPARifTB (Innogenetics, Ghent, Belgium), are available 
to determine MTB susceptibility to RIF. Both assays are reverse hybridization 
assays with a sensitivity for detection of RIF resistance of 98% (Morgan et al., 
2005, Barnard et al., 2008) and 92% (Tortoli and Marcelli, 2007), respectively. 
In South Africa, GenoType MTBDRplus is the line probe assay routinely used in 
the public sector and this thesis will focus on this assay. In the remaining thesis, 
the term “LPA” refers exclusively to the GenoType MTBDRplus assay. 
GenoType MTBDRplus line probe assay  
The GenoType MTBDRplus LPA was incorporated into the routine TB diagnostic 
testing algorithm within the state sector in South Africa in 2008. It replaced routine 
phenotypic DST (i.e. MGIT proportion method) as the first screen for MTB drug 
resistance. At the time, DST by LPA was performed only on patients failing first 
line TB regimens, retreatment patients or on patients suspected clinically to have 
MDR-TB (e.g. having an MDR-TB contact). It was performed on direct sputum 
specimens that are smear positive for AFB, as well as on cultures positive for 
AFB. 
In the most recent TB testing algorithm within the South African TB Control 





been detected by Xpert - confirmation of RIF resistance was recommended in the 
WHO endorsement of the Xpert MTB/RIF assay in 2010. The LPA is also 
performed on a subsequent culture if the initial screening Xpert does not detect 
MTB (Figure 6). 
Principle  
The LPA is a qualitative test for the extraction and identification of MTB and its 
resistance to INH and RIF based on DNA-STRIP technology. For RIF, the 
presence of rpoB mutations is inferred by the absence of hybridization to one (or 
less commonly more) wild type (WT) probe with or without presence of 
hybridization to mutation probe (MUT) in the RRDR of the rpoB gene, spanning 
from codon 505 to codon 533. For INH, the katG and inhA gene are examined. 
The procedure includes DNA extraction from a smear positive respiratory 
specimen or from the culture isolate, multiplex amplification with biotintylated 
primers and a reverse hybridization to membrane strips coated with target-specific 
oligonucleotides. Highly specific binding of complementary DNA strands is 
ensured by stringent conditions (e.g. buffer composition and 45⁰C temperature). 
The reverse hybridization binding is followed by a biotin-streptavidin mediated 
detection of hybridized amplified products (Hain-Lifescience, July 2013). The 
staining that results from the biotin-streptavidin hybridization step results in a band 











Figure 1: Facsimile of “RIF resistant region of the rpoB gene” from LPA MTBDRplus package insert 
version 2. The Rifampicin Resistance Determining Region (RRDR) of the rpoB gene that is included 
in the LPA spans from codon 505 to codon 533 and is divided into 8 WT probes (rpoB WT1-8). 
rpoB MUT1-3 represent corresponding mutation probes for the most commonly encountered 
rpoB mutations in MTB. 
*RIF = rifampicin, LPA = line probe assay, WT = wild type probe, MUT = mutation probe. 
 
Interpretation 
If interpretation is manual, the strip is “read” by the naked eye, using a template 
that is provided in each kit. Interpretation may be performed by an automated 
scanner (Genoscan, Hain Lifesciences) which interfaces with the laboratory 
information system (LIS); this is used in high throughput laboratories such as 
Green Point NHLS (National Health Laboratory Service) in Cape Town. 
Each LPA strip has 27 reaction zones including internal controls. For RIF 
susceptibility, the LPA strip is divided into 12 probes; eight probes represent the 
WT (susceptible) and four MUT probes represent the (4 most common) mutant 
(resistant) sequences of nucleotides within the RRDR of rpoB gene. The LPA 
includes internal quality control bands on the DNA strip which are the conjugate 
control (CC) which verifies the efficiency of conjugate binding and substrate 
reaction for the hybridization of probe to amplicon, the amplification control (AC) 
which verifies that amplification occurred and that there was no inhibition of the 
PCR, and the locus control bands for the rpoB, katG and inhA genes which detect 





The package insert states that a probe band must be interpreted as being present 
if its intensity is equal to or stronger than that of the AC band for that strip. The 
probe band is interpreted as absent if its intensity is less than that of the AC band 







Figure 2: An LPA strip with interpretation template showing all the 27 reaction zones aligned to 
MTB isolate number 8 showing absence of rpoB WT7 and presence of rpoB MUT2B. This is 
interpreted as RIFR. (The isolate strip also shows the presence of all WT katG and inhA bands and 
absence of katG and inhA MUT bands; this is interpreted as INH susceptible). 
* AC = amplification control, LPA = line probe assay, MTB = Mycobacterium tuberculosis, WT = 
wild type, MUT = mutation, RIFR = rifampicin resistant, INH = isoniazid 
 
TUB band 
If present, the TUB band indicates the presence of MTB complex. If the TUB probe 
is absent the specimen/culture is considered negative for MTB complex. The TUB 














Wild type (WT) probes 
Table 1: Interpretation of the LPA. Both A and B must be determined in order to interpret the 
antibiotic result. 
(A) Wild type (WT) probes 
present/absent 
(B) Mutation (MUT) 
probes present/absent 
(A+B) Interpretation of 
drug susceptibility 
Present (all) Absent  Susceptible  
Absent (one or two) Present (usually one) or absent*  Resistant  
Present (all) Present (usually one)  Resistant (heteroresistance) 
*Present: the intensity of the particular band is as strong as or stronger in intensity than the AC 
band.  
*Absent: the intensity is weaker than the AC band. *AC = amplification control 
 
Mutation (MUT) probes 
The presence of a mutation (MUT) band indicates resistance to the drug. The LPA 
incorporates four mutation probes for rpoB. These are the sequences of the most 
commonly encountered rpoB mutations that account for the majority of RIF 
resistance (Telenti et al., 1993, Van Deun et al., 2013). The corresponding amino 
acid change that occurs for each of these rpoB mutations is provided in the 
package insert (Figure 3) (Hain-Lifescience, July 2013). For example, if WT3 and 
WT4 are absent, and MUT1 band is present, it corresponds to rpoB mutation in 
codon 516 called mutation D516V where aspartic acid (D) is replaced by valine 
(V). The remaining three most common rpoB mutations encountered clinically are 
H526Y, H526D where histidine (H) is replaced by tyrosine (Y) and aspartic acid 
(D), respectively, and S531L where serine (S) is replaced by leucine (L). These 
are identified by the following patterns on the LPA: absent WT7 plus present 
MUT2A (H526Y); absent WT7 plus present MUT2B (H526D) and absent WT8 
plus present MUT3 (S531L). 
For the remaining less commonly encountered rpoB mutations, either in the same 
codons 516, 526 or 531 (where aspartic acid, histidine, and serine are replaced 





codons (between 505 to 533), there is no corresponding MUT band incorporated 
in the LPA strip; the replacing amino acid is not encoded for by its known 
sequence in a probe; however, a list of possible amino acid changes is provided 
in the package insert (Figure 3), based in the most commonly encountered 
sequences worldwide (Telenti et al., 1993). These less common rpoB mutations 
are still interpreted and reported as conferring RIF resistance since there is a 
nucleotide substitution/deletion in the WT sequence. The resulting pattern on the 
LPA is absent WT probe band, and absent MUT band. The clinical significance of 
some of these mutations are unknown (Van Deun et al., 2009) and those with an 
asterisk (in package insert; Figure 3) have only been detected “in silico” (not from 
clinical specimens/isolates). Since the corresponding phenotypic RIF result when 
testing at the critical concentration of 1µg/ml with MGIT or with other liquid based 
proportion method DST may be susceptible (thus giving a discordant phenotypic 
result), these rpoB mutations have been termed by some authors as “disputed 
rpoB mutations” (Van Deun et al., 2013, Rigouts et al., 2013).  
In addition to differentiating high level RIF mutations from possible low level / 
susceptible RIF mutations, the LPA is able to also detect heteroresistance for a 
particular drug, as long as the proportion of the mutant population is greater than 
5% in the specimen/culture isolate (Zetola et al., 2014). RIF heteroresistance is 
inferred if all rpoB wild type (rpoB WT) probes are present and (usually) one of 
the rpoB mutation (rpoB MUT) bands is also present. Heteroresistance may be 









Figure 3: Facsimile of “Table of mutations in the rpoB gene and the corresponding wild type and 
mutation bands” from LPA MTBDRplus package insert version 2. LPA has 8 rpoB WT bands (WT1-
WT8) and four rpoB MUT bands (MUT1, MUT2A, MUT2B and MUT3) and spans from codon 505 
to 533. Mutations in the rpoB gene are due to SNPs resulting in a change of amino acid e.g. L533P 
indicates that amino acid leucine (L) in codon 533 was replaced by amino acid proline (P) due to 
a SNP where thymine (T) was substituted by cytosine (codon CTG to CCG). 
*WT=wild type, MUT=mutation, SNP = single nucleotide polymorphism 





Limitations of the LPA that could lead to a false RIF susceptibility testing result 
and thus discordance between LPA and phenotypic DST 
1. The LPA assay screens for SNPs; therefore, there is a possibility that an 
rpoB mutation that does not cause an amino acid change (i.e. a silent 
mutation) will be detected as an absence of wild type probe, and 
interpreted as RIF resistant. 
2. The assay only detects RIF resistance that originates from the mutations 
within the RRDR of the rpoB gene. Resistance due to rpoB mutations 
originating from outside of the RRDR of rpoB gene or due to non rpoB 
genes (Siu et al., 2011) or other mechanisms of resistance (Louw et al., 
2009) are not detected by the LPA. A resulting RIF susceptible (RIFS) result 
by LPA could give rise to a discordant result with phenotypic RIF 
susceptibility testing. 
3. In cases of heteroresistance where both a susceptible and a resistant 
pattern is expected, but resistance is due to a disputed  rpoB mutation (thus 
there will be an absent WT probe and absent MUT probe, the LPA will be 
interpreted as RIFS since only the wild type pattern will be visible on the 
strip. The heteroresistance will be missed by the LPA. 
4. In 2013, the LPA was updated to a 2nd version (“V2”), in order to improve 
the intensity of the bands that developed on hybridization, specifically, rpoB 
WT6, WT7 and WT8. These bands had often looked faint in version 1, 
resulting in uninterpretable results for RIF. In addition to improving the 
intensity of the rpoB bands in V2, the L533P mutation (corresponding to a 
pattern of [WT8 absent and no mutation present]) was excluded from the 
WT8 probe. The reason for this exclusion was that isolates with the L533P 
mutation were found to be phenotypically susceptible to RIF at the critical 
concentration of 1 µg/ml that is used in liquid based DST methods (Van 
Deun et al., 2013). However, this contradicted findings of later studies 
where patients infected with MTB that harboured the L533P mutation were 





significant (Williamson et al., 2012). In a later version of V2, Hain 
reincorporated the L533P into the WT8 probe. 
 
1.5.2.2 Xpert MTB/RIF 
Principle 
The Xpert MTB/RIF (Cepheid, Sunnyvale, USA) assay is based on hemi-nested 
real-time PCR and molecular beacon technology in a closed system for the 
detection of RIFR MTB (Lawn and Nicol, 2011). Mutations in the 81-bp RRDR of 
the rpoB gene (codons 507 to 533) are detected by five overlapping molecular 
beacons. Molecular beacons are single stranded oligonucleotide hybridization 
probes that form a hairpin (i.e. stem-loop) structure. The probe loop is a sequence 
complementary to WT sequence. On either side of the probe loop, there are two 
sequences that are complementary to each other and together form the stem. The 
fluorophore (fluorescent dye) is covalently attached to the one end of the stem 
and quencher (non-fluorescent dye) is covalently attached to the other end 
(Figure 4). When a beacon binds to a matching sequence of DNA from the 
specimen, it fluoresces indicating the presence of one of the WT gene sequences 
that is characteristic of RIFS MTB. If a beacon fails to bind at all or there is delayed 
binding to the matching sequence, it indicates potential RIF-resistance (i.e. 
absence of wild type) (Lawn and Nicol, 2011, Steingart et al., 2014). Cycle 
threshold (Ct) is defined as the number of cycles of PCR that is required for a 
fluorescent signal to occur. This fluorescent signal must exceed the background 
level or cross the threshold, the point at which the fluorescence significantly rises 
above the background level. Delta Ct max (∆Ct max) is defined as the difference 








Figure 4: Molecular beacon operation. The molecular beacon contains a loop region that is 
complementary to the target sequence. The stem region contains complimentary nucleotides 
with a fluorophore and quencher dye attached to either side of the stem arm. When the target 
sequence is present, the stem opens due to the more stable probe-target duplex where the loop 
region of the beacon binds to the complementary sequence, causing the loop to extend resulting 
in the quencher releasing from the fluorophore with an increased fluorescent signal that is read 
by the instrument. In the absence of the target sequence the complementary region in the stem 
remains hybridized keeping the quencher in close contact with the fluorophore and no 
fluorescence occurs. 
 
The Xpert assay detects MTB DNA and RIF resistance at the same time by 
amplifying the RRDR which is probed with five molecular beacons (probes A – E) 
for rpoB mutations (Figure 5). Each beacon is labeled with a different fluorophore. 
The molecular beacons were designed to hybridize the WT sequence of the 
RRDR. If there is a mutation within the RRDR then it interferes with hybridization 
in such a way that the probe is retained in a non-fluorescing state. A mutation(s) 
in the RRDR results in one or more of the corresponding probes to either fail to 
fluoresce completely (termed probe “drop out” and indicated by one or more 
probes with a Ct value of zero) or have a delayed onset of fluorescence (termed 
“probe delay” and calculated by the instrument by subtracting the lowest probe 












Figure 5: rpoB gene rifampicin resistance determining region and molecular beacon technology. 
A) The rpoB gene, the nucleotide sequence of 81bp RRDR and the five (A-E) overlapping 
molecular beacon probes covering the core region. B) A schematic of the molecular beacon in 
stem-loop hairpin conformation. The stem brings the dye and quencher to quench the 
fluorescence. The loop region contains a complementary sequence to the target sequence. 
Hybridization induces a conformational change that leads to separation of the fluorophore and 
quencher resulting in an increased fluorescence signal. (Figure adopted from Lawn, Nicol 2011) 
*RRDR = rifampicin resistant determining region 
 
Automated interpretation by the GeneXpert system is done by using the 
fluorescent signals and embedded calculation algorithms. MTB is reported as 
detected when at least two probes fluoresce within the valid range (Ct value ≤38) 
and the delta Ct min (∆Ct min is the smallest Ct difference between any pair of 
probes) is less than 2. If MTB DNA is detected, the result is reported as High, 
Medium, Low or Very Low depending on the Ct value (Table 2) (Blakemore et al., 
2011, Lawn and Nicol, 2011). The Ct value is indirectly proportional to the baseline 
load of MTB bacteria in the specimen such that a lower Ct value is obtained when 
there is a higher concentration of MTB DNA in the sample and a higher Ct value 
means there is a lower starting concentration of MTB DNA in the sample 
(Blakemore et al., 2011, Lawn and Nicol, 2011). 
 
 





Table 2: Relationship between semi quantitative report results and the actual Ct value 
MTB detected (load) Ct value range of earliest probe 
High ≤16 
Medium 16 < Ct ≤ 22 
Low 22 < Ct ≤ 28 
Very Low 28 <Ct ≤38 
*MTB = Mycobacterium tuberculosis, Ct =cycle threshold 
The RIF result by Xpert is reported as “susceptible” by the instrument if MTB is 
detected and the ∆Ct max is ≤ 4.0.  RIF resistance is reported if MTB is detected 
and the delta ∆Ct max is >4.0 (delay) or MTB is detected and one or more of the 
probes fail to fluoresce at all (dropout: Ct=0) (Cepheid, May 2012). 
Limitation of Xpert assay that may lead to discordant results between Xpert and 
phenotypic DST 
1. The Xpert assay is dependent on the number of organisms present in a 
sample. When the bacterial load is Very Low, it has been reported to lead 
to discordant or/and a false RIFR result (Ocheretina Oksana, 2016). 
2. Reliable results are dependent on proper adherence to recommendations 
supplied by the manufacturer from sample collection, transport and storage 
to correct sample processing.  
3. The assay only detects RIF resistance that originates from mutations in the 
RRDR of the rpoB gene. Resistance due to other mutations originating 
outside the gene regions or other genes or other mechanism of resistance 
will not be detected. 
4. Previous versions of Xpert MTB/RIF:  
a. In 2010-11, false RIF resistance was reported by Xpert MTB/RIF 
(version G3 cartridge); this was primarily due to a delay in 
hybridization and it was determined that the delta Ct max cutoff was 
too high. In light of this, the criteria for determining RIF resistance 
by Xpert when resistance was detected due to a delay in probe 





MTB/RIF cartridge (G4) from ∆Ct max >3.5 to >5 then from  ∆Ct max 
>5 to ∆Ct max  >4 (Lawn and Nicol, 2011).The improved Xpert 
MTB/RIF cartridge G4 has been in use in the South African public 
sector since 2012.  
b. False RIFS results also occurred with the G3 assay as this version 
did not detect the L533P mutation. This was shown in a study in 
Switzerland (Somoskovi et al., 2013) where the presence of the 
mutation L533P was confirmed by sequencing on the corresponding 
culture isolates. Initially two sputum specimens were submitted for 
Xpert testing and MTB was detected on both specimens and RIF-
indeterminate on first sample and RIFR on second sample using G4 
cartridges. Because the patient was from Switzerland (a low MDR-
incident country) the assay was repeated on 4 subsequent sputum 
specimens using G3 cartridges and all four tested RIFS. In addition, 
on repeat testing of the first specimen, using the version G4 
cartridge, RIFR was detected with delayed hybridization (Ct max 
>5) of probe E (that corresponds to L533P). Further analysis using 
MGIT 960 showed RIFS at the critical concentration of 1 µg/ml 
(Somoskovi et al., 2013) which correlates with other findings of 
mutation L533P conferring low level resistance (Van Deun et al., 
2009, Rigouts et al., 2013). 
c. False RIFR results also occurred with the G3 cartridge due to 
problems with probe B. An improvement in the G4 cartridge include 
modification of probe B beacon sequence to reduce false RIFR by 
improving the stability of the wild type hybrid target at an elevated 
annealing temperature. (Other improvements include modification 
of the assay setting and PCR cycling to reduce error rates and false 








1.5.2.3 DNA Sequencing 
Sequencing of known resistance loci 
DNA sequencing remains the gold-standard for genotypic detection of mutations 
conferring TB drug resistance. Currently, Sanger sequencing is the most 
accessible form of DNA sequencing for MTB. The advantages of Sanger 
sequencing include high accuracy  (Sanger et al., 1977) and it can be utilized as 
a reference when validating new sequencing tests. DNA sequencing can be used 
to detect any alterations that confer RIF-resistance in the RRDR of rpoB gene and 
beyond (e.g. upstream or downstream of the RRDR) (Telenti et al., 1997, Musser, 
1995). However, Sanger DNA sequencing for detection of mutations associated 
with MTB drug resistance is not routinely available in most diagnostic laboratories.  
Sanger DNA sequencing is based on the chain termination method to sequence 
a DNA fragment. Once a specific primer binds to the denatured single strand of 
DNA, DNA polymerase initiation occurs and DNA replication begins at the primer 
site. The elongation is terminated when a dye-labeled dideoxynucleotide is 
inserted. This happens because the dye-labeled dideoxynucleotide lacks the 3’-
OH group required for the formation of a phosphodiesterase bond between two 
subsequent nucleotides. The content of the reaction produces DNA fragments of 
various lengths that can be separated via electrophoresis by size and nucleotide 
type and subsequently sequenced (Sanger et al., 1992). 
The major limitation of DNA sequencing testing is that it is costly and not available 
in routine TB laboratories; as such is not routinely used for TB diagnosis within 
the National TB Program.  Its use is restricted to troubleshooting discordant 
results between routinely used test methods (such as Xpert and LPA) or for 
diagnosis when routine methods such as Xpert and LPA provide no conclusive 
results. 
An additional advantage of DNA sequencing is that it is able to detect 
heteroresistance by showing dual peaks chromatogram pattern in the rpoB gene 





Next generation sequencing (NGS) has more recently become more widely 
available and is available in reference / research laboratories in some countries. 
NGS involves shorter read lengths and higher error rates but requires higher 
sequence depth to determine the consensus sequence (Tucker et al., 2009). It 
involves sequencing of the entire genome of MTB, with comparison to a reference 
sequence. NGS will likely soon replace Sanger sequencing as it is high throughput 
and has great potential for TB diagnosis (Pankhurst et al., 2016, Ocheretina et al., 
2015). 
DNA sequencing may be used to resolve discordance between LPA or Xpert and 
phenotypic RIF susceptibility results. 
 
1.6 South African National TB Control Program for patients with 
presumptive TB 
The Xpert assay has been adopted as the initial screening test for patients with 
presumptive TB by the South African National TB Control programme (NTBCP), 
Figure 6. RIF resistance detected by Xpert is confirmed by LPA and/or phenotypic 
DST using MGIT on a culture isolate from a second sputum specimen. 
In the Western Cape Province, two spot sputum specimens are collected one hour 
apart from a patient with presumptive TB and Xpert is performed on one sample. 
The second specimen is stored at 4-8⁰C in the laboratory until further testing 
which is based on the Xpert result (Figure6). 
Where Xpert detects MTB complex that is susceptible to RIF, the patient is started 
on the WHO standard TB drug susceptible regimen and the second specimen is 
processed for TB microscopy only. The microscopy result is used to monitor 
response to treatment and for contact tracing. If Xpert detects RIFR-MTB complex, 
the patient is started on an MDR-TB regimen and the 2nd specimen undergoes 




































Figure 6: South African tuberculosis program diagnostic algorithm incorporating Xpert MTB/RIF 
as the initial screening test. SA NTBCP= South African National TB Control Program, TB= 
tuberculosis, MTB= Mycobacterium tuberculosis RIF= rifampicin, S= susceptible, R= resistant, 
MDR= multi-drug resistant, HIV= human immunodeficiency virus, DST= drug susceptibility 
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Key limitations of the NTBCP algorithm in relation to screening for resistance are: 
1. Rifampicin resistance that (rarely) occurs due to mechanisms other than 
mutations in the RRDR of the rpoB gene will be missed and falsely reported 
as Xpert RIFS (whether tested by Xpert or LPA). The NTBCP laboratory 
testing algorithm guide informs clinicians to submit a specimen requesting 
phenotypic DST if RIFR is suspected despite a RIFS result by Xpert or LPA, 
so that the approximately 2% of RIF resistance that is missed by Xpert/LPA 
can be detected by phenotypic DST. 
2. Xpert is performed directly on a clinical specimen (this specimen cannot be 
used for further testing e.g. culture once it has been processed for Xpert); 
the subsequent confirmatory assay (LPA or MGIT) is performed on a 
culture isolate from a second submitted specimen. Thus, it is possible for 
discordant results in general to arise because the two submitted specimens 
may contain different amounts of TB bacilli, and / or different strains of 
MTB. In addition, specimen mix up / mislabelling may occur before 
specimens reach the laboratory. 
3. INH is not tested 
 
1.7 Discordant rifampicin susceptibility results 
In general, utilizing different test methods to test for the same parameter may 
result in discordance since one method may be superior in sensitivity or specificity 
to the other. It is important to understand the limitation of each assay in 
determining RIF susceptibility. Access to the gold standard method may be 
limited, making it challenging to determine the true result. If only one test method 
is being utilized discordance may arise if testing is repeated for some reason. 
Discordant RIF susceptibility results may arise between two different genotypic 
methods, between a genotypic method and a phenotypic method, or between two 






1.7.1 Discordance between genotypic RIF results (Xpert and LPA)   
Although both the Xpert and LPA target the same rpoB gene region (the RRDR), 
discordant RIF susceptibility results between the two assays have been reported 
(Berhanu R, 2015, Ocheretina Oksana, 2016). 
1.7.1.1 Xpert RIFR: LPA RIFS 
Particular Xpert assay parameters (e.g. bacterial load, delayed probe 
hybridization) have been found to be associated with discordant Xpert and LPA 
RIF results (Berhanu R, 2015) and also with false Xpert RIFR results (Ocheretina 
Oksana, 2016). 
In a study that was performed in Haiti, 2024/9890 (20.5%) respiratory samples 
were Xpert (G4) positive for MTB. Of the 2024, 410 (20.3%) had Very Low MTB 
loads detected by Xpert. From samples with non-Very Low MTB loads, all 87 
(5.4%) which were RIFR on Xpert, were classified true Xpert RIFR because all 
isolates from these patients harboured an rpoB mutation by Sanger sequencing. 
Of the 410 samples with Very Low MTB loads, 35 (8.5%) samples tested Xpert 
RIFR of which only 22/35 had positive cultures. Only 10/22 (45.5%) had an rpoB 
mutation detected by Sanger sequencing of which 8/10 tested RIFR by phenotypic 
DST and 2/10 had silent mutation T508T and were RIFS by phenotypic DST.  
However, 12/22 (54.5%) had no rpoB mutation detected by Sanger sequencing 
and all tested RIFS by phenotypic DST. In addition, LPA was performed directly 
on 11/12 specimens and 10/11 specimens were LPA RIFS (considered a true LPA 
result) and one failed the LPA test. The false Xpert RIF resistance was due to 
probe delay in 91% (10/11) and in 1/11 there was probe drop out of three probes. 
From the 11/12 specimens which had probe delay, there were double probe 
delays of D+E (n=6), probe D (n=4) and probe E (n=1). This study concluded that 
all Xpert RIFR results with a Very Low level of MTB should be confirmed by culture 
based DST prior to reporting and should consider bacterial load of samples to 






A study conducted in India reported 25 discordant RIF results between Xpert (G4) 
and LPA from a total of 145 smear positive sputum samples; 21/25 were Xpert 
RIFS and LPA RIFR, 4/25 were Xpert RIFR and LPA RIFS. rpoB sequencing and 
MGIT DST were performed on all discordant isolates from the same specimen. 
There were 18/21 cases that were shown to be false Xpert RIFS where mutations 
L533P (n=14) and S531L (n=4) were detected on isolates by rpoB sequencing. 
There were 2/21 isolates that were resistant by MGIT DST but no mutation was 
detected by rpoB sequencing and the study could not rule out mixed infection. 
Three of the four cases with Xpert RIFR were categorized as false Xpert RIFR 
because there were no mutations detected by rpoB sequencing and all three were 
RIFS by MGIT-DST. Two (one of each category) could not be confirmed by rpoB 
sequencing or MGIT DST due to contamination (Rufai et al., 2014). Mutations 
detected by four Xpert probes (A,B,C and D) were all concordant with mutations 
detected in similar codon regions by LPA but probe E did not detect a mutation in 
52% of samples that had mutations detected by LPA in similar codon regions (wild 
type 8 absent). All 18 false Xpert RIFS results had LPA RIFR reported due to an 
absent WT8 and absent MUT band in the 14 samples (L533P) and an absent 
WT8 band plus MUT3 present in four samples (S531L). In all 18 cases, the LPA 
pattern corresponded with the rpoB mutation detected by sequencing.  The study 
suggested that each country carry out an evaluation that represents the 
population with each version of the assays because some probes may have 
different utility, geographically (Rufai et al., 2014). 
1.7.1.2 Xpert RIFS: LPA RIFR 
Strydom et al compared three genotypic assays including LPA version 2.0, Xpert 
G3 and the Anyplex MTB/NTM (Seegene, South Korea) on 115 MTB culture 
isolates collected from Tswane Academic Division, NHLS, South Africa. LPA 
version 1.0 was used to select isolates retrospectively. Consecutive isolates were 
selected to make up a calculated sample size of 50 susceptible to both INH and 
RIF, 20 monoresitant (10 INH monoresistant and 10 RIF monoresistant), 20 
isolates with unidentified mutations (absent WT and absent MUT bands) and 30 





and one had poor banding pattern using LPA version 2.0. There were six 
discordant RIF results among the three assays as determined by sequencing. 
Only one isolate had discordant RIF result between LPA and Xpert assays in 
which LPA version 2.0 detected RIF resistance whereas Xpert did not detect RIF 
resistance. Sanger sequencing of the rpoB gene did not detect any mutation. The 
LPA assay showed a heteroresistant pattern for RIF displaying rpoBMUT3 band 
and the isolate tested RIFR by MGIT DST at 1.0 µg/ml (Strydom et al., 2015). 
Xpert was reported to miss RIF resistance in a mixed population due to wild type 
masking effect which is one of the limitations of the Xpert assay (Lawn and Nicol, 
2011). This discordance phenomenon would not be detected by the routine 
diagnostic algorithm of the NTBCP and will not be the focus of this dissertation. 
The focus of this dissertation will be the phenomenon of discordance Xpert RIFR: 
LPA RIFS, where the Xpert reports MTB resistant to RIF and the LPA reports MTB 
that is susceptible to RIF. This is the most common discordant scenario for the 
genotypic tests that is encountered in SA, since screening for MTB according to 
the routine diagnostic algorithm of the SANTBCP starts with Xpert (Figure 6). 
 
1.7.2 Discordance between genotypic and phenotypic RIF results 
Not all rpoB mutations confer the same level of RIF resistance; some mutations 
confer high level resistance (a high RIF MIC) which typically results in a 
concordant phenotypic RIFR result with liquid based (MGIT) DST. Some mutations 
confer low level or “borderline” RIF resistance which would be missed by liquid 
based (e.g. MGIT) DST and thus give a discordant RIF result. 
1.7.2.1 Discordance between genotypic and phenotypic RIF results, 
specifically RIFR (genotypic) and RIFS (phenotypic) 
Low level rifampicin resistance occurs when both liquid and solid media 
phenotypic DST results show susceptibility to RIF at the routine critical 
concentration recommended for each method (no discrepancy between the two 





/ or rpoB sequencing) detects an rpoB mutation (Van Deun et al., 2009, Van Deun 
et al., 2013). For low level RIF resistance, the MIC lies between 0.5 and 0.0625 
µg/ml. 
Borderline rifampicin resistance is defined as a discrepancy between liquid and 
solid culture based DST methods, with the liquid-based phenotypic DST method 
reporting RIFS but solid method phenotypic DST reporting RIFR (Van Deun et al., 
2013, Van Deun et al., 2009) and genotypic testing detecting an rpoB mutation 
and the MIC is >0.5 and ≤1.0 µg/ml.  
The rpoB mutations that confer to either low level or borderline rifampicin 
resistance have been termed disputed rpoB mutations (Van Deun et al., 2009, 
Van Deun et al., 2013, Rigouts et al., 2013). 
Over a six-month period in 2009, in the NHLS Braamfontein TB laboratory, 
Johannesburg, the LPA detected rpoB alterations in single isolates from 422 
patients, of which 396 (93.8%) had concordant RIFR results using the MGIT DST 
method at the critical concentration of 1 µg/ml. Of the isolates with concordant 
RIFR results; 371/422 (88%) isolates had one of the four most commonly 
encountered rpoB mutations (S531L, H526D, H526Y or D516V). The remaining 
51/422 (12%) of rpoB mutations were those less commonly encountered, 
identified by the LPA as having “an absent rpoB WT band and no corresponding 
MUT band”; in 26/51 (51%) the MGIT result was susceptible to RIF (Beylis N, 
2012). 
Van Deun et al. studied MTB isolates from 19 TB-confirmed patients who were 
failing the standard susceptible TB regimen, and detected a discrepancy between 
genotypic and liquid-based phenotypic DST methods for RIF whereby isolates 
which had rpoB mutations conferring RIF resistance were susceptible to RIF by 
MGIT DST (Van Deun et al., 2009). The study recommended that a prolonged 
incubation time and a larger inoculum size may be necessary to detect the 
resistance of poorly growing low-level RIF-resistant strains and that the RIF critical 





Rigouts et al. showed similar results in that MGIT DST failed to identify RIF 
resistance in isolates harbouring certain, less common, RIF resistance-conferring 
mutations associated with low level resistance – these mutations were associated 
with poor clinical outcome and therefore appear to be clinically relevant (Rigouts 
et al., 2013). The mutations were L511P, D516Y, H526N, H526L, L533P, I572F 
and these mutations have been reported to confer low level RIF resistance in 
other studies (Ohno et al., 1996, Van Deun et al., 2011, Van Deun et al., 2013). 
The critical concentration of RIF for liquid DST methods such as MGIT is 1.0 
µg/ml; however, the relevance of this concentration to microbiologic and clinical 
outcomes is unclear. Gumbo used antimicrobial pharmacokinetic / 
pharmacodynamic (PK/PD) parameters and population pharmacokinetic 
variability using Monte Carlo simulation to conclude that the critical concentration 
for RIF should be lowered to 0.0625 µg/ml (Gumbo, 2010). 
Similarly, a study by Bottger et al. has criticized the DST method used for MTB 
where the critical concentration is an epidemiological cutoff and is not based on 
clinical outcome information or PK/PD parameters, as is done for routine 
bacteriology testing (Bottger, 2011). The study further emphasizes the importance 
of MIC testing for MTB in assisting the clinician in developing individualized 
regimens for drug-resistant TB. The level of RIF resistance seems to correlate 
specifically with the particular codon in the rpoB RRDR region, and in addition 
with the actual SNP/amino acid change that occurs within that codon (Ohno et al., 
1996). 
In the study performed in Haiti, 153 consecutive clinical isolates resistant to RIF 
by both Xpert and LPA were selected and tested phenotypically by MGIT and 
solid agar for RIF susceptibility. There were 16 isolates which were susceptible to 
RIF by the MGIT DST method and 11 on solid media at the respective critical 
concentration. The RIF MIC was determined using the microplate assay for all of 
the discordant isolates. Five isolates were classified as borderline RIFR, with rpoB 
mutations H526L (n=4) and H526C (n=1). Nine isolates were classified as low 





0.25 µg/ml and with double mutations L511P and M515T (n=2) with MIC values 
between 0.25 and 0.5 µg/ml. The remaining two isolates from two patients 
harboured an identical silent mutation, a SNP inT508 (AAC-ACT); both were 
susceptible at the lowest MIC (0.031 µg/ml) tested. It was concluded that it is 
necessary not only to detect the presence of an rpoB mutation, but also to identify 
the mutation in order to accurately diagnosis RIF resistance. The study also 
suggested creating a user-friendly database that determines links the specific 
rpoB mutation to its level of RIF resistance (MIC) (Ocheretina et al., 2014). 
In a study conducted in Australia, rpoB sequencing was performed on 214 
consecutive isolates that were phenotypically (MGIT) RIFS but resistant to other 
first line drugs (202 were INH mono-resistant and 12 had other resistance 
patterns). Of the 214 isolates, 207 had rpoB sequencing results of which five had 
rpoB mutations; L511P (n=3), D516G (n=1) and L533P (n=1) and 202 had no 
rpoB mutation detected. RIF MIC testing was performed using the MGIT method 
at concentrations between 0.12 and 1 µg/ml. Isolates with the mutations L511P 
(n=1) and L533P (n=1) had an MIC value of 1.0 µg/ml and isolates with L511P 
(n=1) and D516G (n=1) had an MIC value of 0.5 µg/ml. The remaining isolate with 
mutation L511P had an MIC value of 0.25 µg/ml. On average, the MIC values of 
the five isolates with an rpoB mutation were 7.3 times higher than the control 
group of 12 isolates (that were all fully susceptible with no rpoB mutation). This 
difference was statistically significant p<0.0001 (95% CI 3.9 -13.7) (Ho et al., 
2013). 
A study from New Zealand described 94 MTB isolates that were resistant to INH 
and susceptible to RIF by MGIT DST. Xpert as well as rpoB sequencing was 
performed retrospectively on the stored isolates. rpoB mutations were detected in 
four cases and all four rpoB mutations were so-called disputed (low level 
resistance) mutations, single or combined (L511P and M515I, H526N and A532V, 
D516Y and H526L) (Williamson et al., 2012). 
A study conducted in Germany selected 143 stored isolates that were INH-





mutations by sequencing. Four (2.8%) isolates had at least one rpoB mutation 
within the RRDR, two isolates had L533P with a MGIT MIC value of 0.5 µg/ml, 
one had double mutations D516Y and N518D with an MIC value of ≤0.25 µg/ml 
and the remaining one had double mutations D516Y and E510H with an MIC of 
1.0 µg/ml (Andres et al., 2014). 
 
Table 3: rpoB mutations described to confer low level RIF resistance and their MIC values 
Mutations (n) MIC value (µg/ml) Reference 
L511P (5) 0.125 to 0.25  (Ocheretina et al., 2014) 
L511P (3) 0.25, 0.5 and 1.0 (Ho et al., 2013) 
D516G (1) 0.5 (Ho et al., 2013) 
D516Y  (1) 0.25 (Williamson et al., 2012) 
H526L (4) 0.5 to 4.0 (Ocheretina et al., 2014) 
H526L (1) 0.5 (Williamson et al., 2012) 
L533P (1) 1.0 (Ho et al., 2013) 
L533P (2) 0.5 (Andres et al., 2014) 
L511P and M55T (2) 0.25 to 0.5 (Ocheretina et al., 2014) 
L511P and M55I (1) 0.5 (Williamson et al., 2012) 
D516Y and N518D (1) ≤0.25 (Andres et al., 2014) 
D516Y and E510H (1) 1.0 (Andres et al., 2014) 
H526N and A532V (1) 0.5 (Williamson et al., 2012) 
 
A silent mutation in the rpoB gene is a mutation that does not result in an amino 
acid change of the protein and does not alter the phenotype of Mycobacterium 
tuberculosis against RIF (i.e. would be true RIFS). Both Xpert and LPA would 
detect a silent mutation situated within the RRDR that would result in a false 
genotypic RIFR result, and a discordant phenotypically susceptible result. Silent 
mutations have been described to cause discordance between genotypic and 
phenotypic test methods and if reported as RIFR have the potential to lead to 
improper management of patients (Mathys et al., 2014, Alonso et al., 2011, 








1.7.2.2 Discordance between genotypic and phenotypic RIF results, 
specifically RIFS (genotypic) and RIFR (phenotypic) 
Since more than 95% RIFR MTB strains contain a mutation in the RRDR of the 
rpoB gene (Telenti et al., 1993) and Xpert and LPA utilize the RRDR to detect 
mutations, both assays may miss a small proportion of MTB RIF resistance due 
to other mutations or mechanisms. Several mutations outside the RRDR have 
been reported as being associated with RIF resistance. rpoB mutation V176F was 
shown to be associated with high level of RIF resistance with MIC value 256 µg/ml 
(Heep et al., 2001). V146, I572F were also shown to be associated with high level 
RIF resistance (McCammon et al., 2005, Siu et al., 2011). These mutations would 
not be detected by any genotypic assay targeting the RRDR. 
Heteroresistance in MTB may be a cause of discordant laboratory test results. 
Heteroresistance is defined as the presence of both susceptible and resistant 
bacteria in a specimen or MTB culture. It may be due to a mixed infection (the 
presence of different clones of MTB in the same patient) or due to one clone of 
MTB that has evolved over a shorter period of time from susceptible to resistant, 
so that both are detected by the laboratory test(s). The detection of 
heteroresistance is important for patient management (Richardson et al., 2002, 
Cohen et al., 2012); however, detection is challenging and very dependent on the 
method that is used (Shamputa et al., 2006, Hingley-Wilson et al., 2013, 
Folkvardsen et al., 2013, Zetola et al., 2014). 
The LPA is able to detect RIF resistance in mixed infection if the resistance is due 
to a high confidence mutation (one that confers high level RIF resistance (i.e. 
pattern of all WT bands are present plus a MUT band is present) and if more than 
5% of the population is resistant (Tolani et al., 2012, Folkvardsen et al., 2013). If 
resistance is due to a disputed rpoB mutation, it will not be detected by the LPA 
due to lack of a corresponding MUT band. In one study, the phenotypic assay 
(MGIT 960) was found to be more sensitive in detecting resistance within a mixed 





Discordance manifest as genotypic RIFS: phenotypic RIFR will not be the focus of 
Part 2 of this dissertation. 
 
1.7.3 Discordance of rifampicin results between different phenotypic assays 
MGIT RIFS: LJ RIFR 
Both LJ (solid) and MGIT 960 (liquid) DST are based on the agar proportion 
method but discordant RIF susceptibility results have been reported between the 
two assays (Van Deun et al., 2009, Van Deun et al., 2013). This may be related 
to the different critical concentrations used and to the particular rpoB mutation that 
is responsible for the resistance. Discordance between different phenotypic 
assays is not the subject of this dissertation. 
 
1.8 Clinical relevance of discordant susceptibility testing results 
 
1.8.1 Discordant genotypic RIF results: Xpert RIFR versus LPA RIFS 
The studies that described discordance between Xpert and LPA did not include 
any information about patients’ clinical outcomes (Ocheretina Oksana, 2016, 
Berhanu R, 2015). Discordant results would be expected to cause confusion for 
the clinicians and may lead to mismanagement and possible poor clinical outcome 
as well as possibly to continued transmission, e.g. if a patient with false resistance 
is treated for MDR when the patient has susceptible TB and vice versa. Labeling 
a patient as having MDR-TB may also lead to psychological stress for the patient 
as well as have implications for their employment. 
 
1.8.2 Discordant genotypic versus phenotypic results   
In an observational cohort study performed in China, outcomes of patients with 





patients who were treated with a drug-resistant regimen, than in those treated with 
a susceptible-TB regimen (Pang et al., 2014). 
The clinical importance of discordant RIF results of MTB strains with “disputed 
rpoB mutations” remains unclear despite some studies reporting poor clinical 
outcome of patients infected with these strains. However, the studies are mostly 
observational case series with very small sample sizes. When RIF resistance is 
highly likely despite a susceptible phenotypic result, an alternative genotypic 
assay (such as sequencing) will assist in determining whether the MTB strain 
harbours a mutation conferring low level resistance. MIC testing will determine 
the level of RIF resistance. The frequency of strains with low level RIF resistance 
might be underestimated especially where liquid-based phenotypic susceptibility 
methods are utilized as the primary DST screening test.  
The frequency as well as the nature of discordant RIF susceptibility results 
between Xpert and LPA should be examined. In addition, the clinical implications 
of discordant RIF results between Xpert and LPA should be described. 
Since the current NTBCP laboratory diagnostic algorithm employs two genotypic 
tests used consecutively, discordant results may arise between them and also 
between the two and a subsequent phenotypic DST, if performed. Phenotypic 
DST (MGIT in the case of NTBCP algorithm) is often used to determine the true 
RIF result in a case of discordant Xpert and LPA. Phenotypic DST for RIF is 
limited, however, as rpoB mutations giving rise to low level RIF resistance, will 
test susceptible on MGIT testing at a concentration of 1 µg/ml.  DNA sequencing 
may therefore be a useful adjunctive test to determine which the true susceptibility 
result is. 
In cases of discordant Xpert/LPA RIF susceptibility results there are no clear 
guidelines available in South Africa with regards to managing the patient and there 
is no clear laboratory trouble-shooting algorithm on how to further investigate the 
discordant RIF results. There is no standard method of reporting the discordant 





readily available. In addition, the prevalence of discordant Xpert and LPA RIF 
results in South Africa is not known. 
The prevalence of potential disputed rpoB mutations prevalence in South Africa 
is also not known. In addition, the clinical significance and optimal regimen for 
treatment of patients infected with MTB strains harbouring these rpoB mutations 

























The overall aim is to describe the two most commonly encountered discordant 
RIF results encountered in the routine NTBCP testing algorithm of South Africa. 
1. Discordant Xpert:LPA results 
a. To determine the frequency of discordant Xpert RIFR and LPA RIFS 
results in Cape Town 
b. To determine whether the discordance between an Xpert RIFR and 
LPA RIFS is due to a  
i. false Xpert RIFR result, or  
ii. false LPA RIFS result; 
c. To identify the underlying reason for false Xpert and false LPA 
results 
d. To develop a laboratory trouble-shooting algorithm for laboratories 
to assist in decreasing the frequency of discordant Xpert:LPA 
results 
i. To determine, from our data, whether there are any risk 
factors in the Xpert/LPA test parameters that are associated 
with false RIF results, and 
ii. To develop a guide for laboratories to use to determine when 
a possible false result occurs so that this is not reported 
2. Discordant genotypic RIFR (Xpert or LPA) and phenotypic RIFS (MGIT) 
results for RIF 
a. To determine the frequency and types of miscellaneous rpoB 
mutations as identified by the LPA in Cape Town, South Africa. 
Miscellaneous rpoB mutations we define as any rpoB mutation 
detected by the LPA that is not a high confidence (non-disputed) 
rpoB mutation. The specific pattern on the LPA that determines a 
miscellaneous rpoB mutation is any absent rpoB wild type band and 
absent rpoB mutation bands 






c. To determine which of the miscellaneous rpoB mutations correlate 
with high level RIF resistance and which lead to low level / no RIF 
resistance (and thus would be disputed rpoB mutations)   
d. To develop a database for all miscellaneous rpoB mutations 
detected in this study that will potentially assist clinicians with 







CHAPTER 2  
2. METHODOLOGY 
 
2.1 Summary of study design 
The study was conducted in two National Health Laboratory Service (NHLS) TB 
laboratories in Cape Town, South Africa: Green Point Complex TB laboratory (GPT) and 
the microbiology laboratory at Groote Schuur Hospital (GSH). 
As per the South African NTBCP TB diagnostic algorithm, all Xpert RIFR results are 
confirmed by LPA performed directly on second specimen or on a culture isolate obtained 
from a second specimen. 
Part 1: Discordant Xpert RIFR and LPA RIFS 
Part 1 of the study includes MTB isolates from patients with discordant Xpert RIFR and 
LPA RIFS results in the study period. Sanger sequencing of the rpoB gene from codon 
462 to 591 was performed to determine which of the Xpert or LPA was the false test 
result. The sequencing was performed on the same culture isolates on which LPA had 
been routinely performed. (Isolates that had disputed rpoB mutations by Sanger 
sequencing underwent MIC testing by the MGIT 960 system and EpiCenter TB eXiST 
software with RIF concentrations 0.0625, 0.125, 0.25, 0.5 and 1 μg/ml as they were also 
included in Part 2 of this study).  
A comparator group of isolates for Part 1 was included. These were isolates from 
specimens that had been submitted during the same study period that had concordant 
Xpert RIFR and LPA RIFR results. These specimens were routinely processed in the same 
way as the discordant isolates’ specimens. The comparator group isolates did not 
undergo rpoB sequencing because funding was limited; however, we considered them 
true RIFR since the Xpert and LPA RIF results were concordant (both resistant) and the 
probes indicating the location of the mutation corresponded with each other e.g. if there 





The same Xpert parameter results that were analyzed for the discordant group were 
available for the comparator group. 
Part 2: Discordant genotypic (LPA) RIFR and phenotypic (MGIT) RIFS results 
Part 2 of the study includes MTB isolates that were interpreted and reported according to 
the LPA package insert as RIFR, specifically with an LPA pattern of an absent WT band 
with no MUT bands detected (irrespective of whether an Xpert result was available). We 
termed these “miscellaneous rpoB mutations”; they were all rpoB mutations detected by 
the LPA except the 4 high confidence rpoB mutations S531L, H526Y, H526D and D516V. 
At this point of selection, we did not know what the corresponding RIF MIC would be 
(whether susceptible (≤0.0625 µg/ml), “low level” (between 0.125 µg/ml and 1µg/ml) or 
high level (>1 µg/ml)). 
A comparator group of isolates for Part 2 was included. This comprised isolates from 
routinely processed LPA batches during the study period that were LPA RIFR (by virtue 
of an LPA pattern of an absent WT band plus a present MUT band i.e. a high level rpoB 
mutation); some of these were also used as high level RIFR controls. Isolates that were 
LPA RIFS (where sequencing detected no mutation) were used as RIFS controls 
(expected MIC ≤0.0625 µg/ml). 
All isolates selected for Part 2 of the study and the comparator group underwent rpoB 
sequencing and MIC testing with RIF concentrations of 0.0625, 0.125, 0.25, 0.5 and 1 
μg/ml. 
 
2.2 Selection of isolates to be tested 
Specimens from patients being routinely tested for TB were submitted to various NHLS 
laboratories for initial Xpert testing according to the NTBCP algorithm (Figure 6). With the 
roll-out of Xpert in the NHLS, many peripheral (non-TB-culture) laboratories perform Xpert 
on the first specimen and then refer the second specimen to a central TB culture 
laboratory, either the GPT or GSH laboratory. Peripheral NHLS laboratories that 
performed Xpert on specimens from patients that are included in this study are Tygerberg 





included in the study were seen by clinics and hospitals serviced by these peripheral and 
central NHLS laboratories. 
 
2.2.1 Inclusion criteria for Part 1 isolates (Xpert RIFR and LPA RIFS) 
1. An MTB isolate with an LPA RIFS result, for which the patient had a recent (within 
7 days) Xpert RIFR result. In most cases, the specimen for Xpert would have been 
submitted on the same day as the specimen for which culture and LPA was 
performed. Specimens collected more than one week apart were excluded from 
the study. 
2. The isolates selected were from specimens that had been submitted to the NHLS 
laboratories between 1 January 2014 and 31 October 2015.  
3. The comparator isolates: 
i. Were selected retrospectively using the laboratory information 
system (LIS). 
ii. Were from specimens that were submitted to both GPT and GSH 
laboratories during the study period. 
iii. Included consecutive isolates with a LPA RIFR result that was 
concordant with a recent (i.e. within seven days) Xpert RIFR result 
for the same patient 
iv. Underwent no further tests to confirm RIF resistance; however, the 
probes involved in resistance for both the Xpert and the LPA 
corresponded 
Discordant isolates that fit the inclusion criteria for Part 1 of the study were identified in 
one of two ways: 
1. Staff in the laboratory performing the LPA noticed the discordant Xpert RIF result 
During the routine review of a batch of LPA results, isolates with LPA RIFS results are 
checked against the patient’s corresponding Xpert result using the LIS. If the Xpert RIF 





comment was added onto the laboratory LPA report acknowledging the discordant 
results. A statement was added that further testing was to be performed and to call the 
laboratory for further information.  Isolates from GPT laboratory were sent to GSH 
laboratory for further testing that included phenotypic DST to RIF at a critical 
concentration of 1µg/ml (using MGIT method) and rpoB sequencing. 
2. The clinician / nurse managing the patient noticed the discordant result and 
informed the laboratory 
This usually occurred when the Xpert test was performed at a peripheral laboratory. A 
comment acknowledging the discordant result and informing the clinician of further testing 
to be performed was added to the lab report. If the LPA had been performed at GPT 
laboratory, the isolate was referred to GSH for further testing. 
 
2.2.2 Inclusion criteria for Part 2 isolates (LPA RIFR and MGIT RIFS) 
1. MTB isolates with the specific LPA pattern of [absent WT band and absent MUT 
band]. Thus this group includes all rpoB mutations detected by the LPA except the 
more commonly encountered “high confidence” rpoB mutations (specifically 
S531L, H526D, H526Y and D516V) that confer high level RIF resistance (which 
are identified by an LPA pattern of [absent WT band plus present MUT band]). 
Consecutive isolates meeting this criterion were selected from routine LPA batches 
of GPT and GSH TB laboratories. 
2. The corresponding specimens for these cultures were submitted between 01 
November 2014 and 31 May 2015. 
3. Comparator isolates  
a. Isolates with concordant results between LPA and MGIT (i.e. both LPA RIFR 
and MGIT RIFR, and LPA RIFS and MGIT RIFS) were included from the 
same period of study 






i. The isolates were selected from the most recent batch of LPA that 
was performed and one isolate was selected for each batch of 
sequencing and there were a total of 15 isolates 
1. RIFR isolates had MGIT RIF resistant result and on LPA had 
one rpoB WT probe absent and one rpoB MUT probe present 
(high confidence / high level rpoB mutations) 
2. RIFS isolates had a MGIT RIF susceptible result and on LPA 
had all rpoB WT probes present and absent rpoB MUT probes 
c. Were from specimens that were submitted to both GPT and GSH 
laboratories 
d. Underwent sequencing and MIC testing the same way as the case isolates 
e. Underwent reproducibility testing by repeating rpoB PCR and rpoB 
sequencing 
Table 1: Comparison of codons analyzed by both Xpert and LPA; MTB isolate exhibiting rpoB 
mutation L511P would have an Xpert mutation in probe B (drop out or delay) and an LPA pattern 
of absent WT2 
Xpert LPA 
 Codons analyzed  Codons analyzed 
Probe A 507 512 WT1 505 509 
Probe B 511 517 WT2 510 513 
   WT3 513 517 
Probe C 516 526 WT4 516 519 
   WT5 518 522 
Probe D 522 529 WT6 522 525 
   WT7 526 530 
Probe E 528 533 WT8 530 533 









2.3 Laboratory Test Methods 
2.3.1 Xpert MTB/RIF  
Procedure 
Routine Processing 
The peripheral and central NHLS TB laboratories that routinely perform Xpert testing 
make use of a NHLS standard operating procedure (SOP) that all NHLS laboratories are 
expected to follow (NHLS GPL3695, 2014); this SOP is in keeping with the manufacturer’s 
instructions. In addition, NHLS laboratories performing Xpert are expected to adhere to 
an external quality assurance programme (EQA)(NHLS GPL3964, 2016). Participation in 
the EQA programme by the laboratories involved in this study was 100% and all received 
100% in both EQA rounds during the study periods in 2014 and 2015. 
Xpert interpretation 
The interpretation was performed by the instrument, according to set algorithms 
developed by the manufacturer. All parameter results including MTB detection, RIF 
susceptibility, Ct values and bacterial loads were automatically determined and 
interpreted by the GeneXpert system and downloaded onto the LIS. The results were 
archived according to the manufacturer’s instructions by qualified and competent 
technologists. 
Quality control 
Internal and external controls were included by each laboratory according to the 
prescribed SOP (NHLS GPL3695, 2014, NHLS GPL3964, 2016). 
Study processing / analysis of Xpert 
For each included isolate, the Xpert probe parameters were recorded and it was 
determined whether resistance was due to probe drop-out or probe delay. In the case of 
probe delay, the investigators determined the Ct max value by subtracting the earliest 
probe Ct value from the latest probe Ct value. The probe(s) involved in delayed 
hybridization or drop-out were also recorded. The graphs generated by the Xpert 





2.3.2 GenoType® MTBDRplus Line Probe Assay (LPA)  
Procedure 
Routine sample processing 
Specimens were decontaminated using N-acety-L-cysteine- sodium hydroxide (NaOH-
NALC) to a final concentration of 1% or 1.5% at GPT and GSH laboratories, respectively. 
This is in accordance with the MGIT manufacturer’s instructions (Siddiqi SH, 2006). 
After refrigerated centrifugation at 3000×g, the sediment was re-suspended in 
approximately 0.5 ml of phosphate buffer. Then, 0.5 ml was inoculated into a MGIT tube 
and incubated according to manufacturer’s instructions. Once the MGIT culture became 
positive and the culture was determined to be Ziehl Neelsen (ZN) positive for AFB (Ruiz 
et al.), LPA was performed on the culture. 
The extraction and amplification procedures of the LPA were performed according to the 
manufacturer’s instructions (Hain-Lifescience, July 2013). This assay was performed as 
a routine diagnostic procedure in both GPT and GSH laboratories. 
Routine interpretation and reporting  
The results were interpreted as per manufacturer’s instructions (Hain-Lifescience, July 
2013). 
The high throughput GPT laboratory uses the GenoScan (Hain Lifesciences) to interpret 
the LPA strips. The interpretation read-out as well as the image of the strips is available 
on the computer for reading, archiving and printing. Individual strips were stuck onto the 
worksheet for manual interpretation, if this was deemed necessary. The smaller GSH 
laboratory does not use GenoScan since it processes smaller numbers of LPA; routine 
interpretation was performed manually. The LPA strips were stuck onto the LPA 
worksheet that is provided by the manufacturer with adhesive tape. Interpretation on the 
worksheet was performed by the technologist using the template card provided in the kit. 
Routine result entry and review 
At GPT laboratory, entry of the LPA results into the LIS was through the interface. A 





using the printout of the strips from the scanner. At GSH laboratory, a technologist 
interpreted the results which were subsequently checked (not-blinded) by another 
technologist to ensure quality and minimize any interpretation errors. After agreement, 
one of the technologists would enter the result manually onto the LIS, and the result was 
then reviewed by a pathologist using the LPA worksheet with adhered strips. 
During routine review of each LPA result, the pathologist would check all other TB results 
for the patient on the LIS; this included the corresponding Xpert as well as other LPA 
results, if any, on other specimens. At the GSH laboratory, if on review of an LPA RIFS 
result it was found that the patient had a recent Xpert RIFR result; the LPA was repeated 
from the culture to exclude any laboratory error / mix up. If the repeat LPA RIF result 
remained RIFS, the isolate was selected for inclusion in the study and further testing. If 
repeat LPA was RIFR (concordant with Xpert), the isolate was not included in the study. 
This repeat testing did not routinely occur at the GPT laboratory; the culture was instead 
referred to GSH laboratory for further testing (routine (reported) MGIT DST and 
sequencing (for study purposes only).  Xpert testing of the culture isolate was not 
performed due to budgetary constraints, and repeat Xpert testing of the first specimen 
was not possible since the specimen would have been discarded (and would have been 
too old for repeat testing at the time discordant results were recognized). 
Quality control 
Internal and external controls were included in every batch of LPA processed by each 
laboratory according to the prescribed SOP (NHLS MIC1645, 2014). 
Study processing / analysis of LPA for the study  
1. Repeating the LPA 
The LPA was repeated retrospectively for all discordant isolates from GPT that were 
included in Part 1 of the study to determine whether the error (in the case of false LPA 
RIFS) was with the procedure, or with interpretation. This repetition was performed 
between two and six weeks after routine results had been obtained and the repeat was 
performed on the same MGIT culture (aliquot) isolate referred from GPT to GSH for 





SOP (NHLS MIC1645, 2014). The LPA was not repeated for the comparator group 
because all the probes involved in resistance for the Xpert corresponded to the probes 
on the LPA. 
2. Repeating the interpretation  
Repeat interpretation of the routinely performed LPA, interpretation of repeat LPA and 
comparison of routinely processed and repeat LPAs were performed as follows: 
a. Photos were taken from the computer of the routinely processed LPA strips 
that had been archived by the GenoScan scanner at the GPT laboratory. The 
routinely processed LPA strips from GSH laboratory were still available on the 
original worksheet. This step was a blinded exercise where each LPA was 
interpreted according to manufacturer’s instructions without referring to the 
original interpretation and without referring to other (e.g. Xpert, phenotypic 
DST or sequencing) available results. Two investigators independently 
performed the “new” interpretation and their results were compared. 
b. Isolate mix up as a cause for discordant results was looked for by examining 
strips within a particular LPA batch that included a case patient (patient with 
discordant Xpert/LPA results)’s LPA. For example, if the case patient’s Xpert 
RIFR result indicated a mutation in probe D, LPAs in the same batch that had 
a WT absent in WT probe 7 were examined and the corresponding patient’s 
own Xpert and other results were checked to make sure that that patient’s own 
Xpert/LPA/other TB results were all concordant with the patient’s LPA result. 
c. The false LPA RIFS isolates were stratified into four categories after analyzing 
all available results (i.e. repeat interpretation of the original LPA, repeat LPA, 
sequencing, Xpert and phenotypic susceptibility tests). The 4 categories are 
Technical error, mixed infection, Laboratory mix up, and Indeterminate (Table 
2). 
i. Technical error: 
1.  “Questionable interpretation”:  The routine and repeated LPA 





routine and repeat LPA (by study investigator) differs from 
what was reported for the routine LPA 
2.  “Procedure error”: The pattern of rpoB WT bands on the repeat 
LPA is different to the pattern on the strip of the routine LPA. 
ii. Mixed infection: Mixed infection was determined either by LPA or by 
sequencing results. If the LPA showed heteroresistance where all 
WT and MUT probes were present for an antibiotic the case was 
deemed to have mixed infection. Mixed infection was also deemed 
likely when sequencing was performed on 2 or more isolates from 
the same patient and contradicting results (one WT and the other 
with mutation) were found. 
iii. Laboratory mix-up: The repeat LPA shows a RIFR pattern. The 
routine LPA shows a susceptible pattern, the interpretation of which 
(by study investigator) does not change (susceptible). Laboratory 
mix-up was determined to have definitely occurred when the LPA 
batch containing the false RIFS LPA strip (apparently belonging to 
the case patient) was examined and another LPA strip (apparently 
belonging to an unrelated patient) was found in the batch that has a 
pattern for RIF resistance, specifically matching the involved Xpert 
probe for the case patient (e.g. LPA for unrelated patient has absent 
WT8 and case patient’s MTB mutation is in the corresponding Xpert 
probe E). In addition, on searching the LIS database, another TB 
result (from a specimen taken within one week of the LPA specimen 
receipt date) for the unrelated patient is found which is RIF-
susceptible. Thus, the unrelated patient has true RIF-susceptible TB. 
iv. “Indeterminate”: The cause of the discordance is uncertain. The 
repeat LPA pattern is the same as that of the original; both have 
presence of all 8 rpoB WT bands that are as intense or more intense 
than the AC band and are also as intense as each other (no rpoB 





and there is no MUT band present.  The interpretation of repeat LPA 
is not different to interpretation that was reported for the routine LPA 
or the interpretation by study investigator of the routine LPA. Thus, 
the interpretation is not questionable (all rpoB WT bands are clear 
and as intense as the AC as well as all other rpoB WT bands), and 
procedure error has not occurred as the repeat LPA shows the same 
pattern as the original LPA pattern. However, the following cannot be 
ruled out: 
1. Specimen (pre-laboratory) or isolate (laboratory) mix-up (on 
examining LPA batches, no obvious mix-ups were found); 
2. Mixed infection since multiple specimens were not submitted 
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2.3.3 DNA sequencing of the rpoB gene of Mycobacterium tuberculosis 
Isolate retrieval 
For isolates that were selected at GSH laboratory, the primary MGIT cultures were 
available and used for sequencing. These had been stored at room temperature for 
periods ranging from one to 4 weeks. For isolates that were selected at GPT laboratory, 
an aliquot of the primary culture was transported at room temperature to the GSH 
laboratory for testing. 
Procedure 
2.3.3.1 rpoB PCR 
Preparation of template  
MGIT cultures were mixed by vortexing and an aliquot of 200 µl was transferred into a 
labeled clean Eppendorf tube (2ml screw cap). The aliquot was boiled at 95-100°C for 30 
minutes. The mixture was centrifuged at 12000×g for 5 minutes and 100 µl of the 
supernatant was transferred to a clean tube and used as template DNA. The extracted 
DN/A was stored at 4°C until required. Two µl of the extracted DNA was added to 18 µl 
of PCR master-mix for the PCR reaction. The remaining extracted DNA was stored at -
20°C (NHLS MIC1645, 2014). 
PCR amplification 
A segment of the rpoB gene starting at codon 462 and ending at codon 591, containing 
the RRDR (507-533), was amplified by PCR using the following primers: (Ho et al., 2013). 
rpoB-F: 5’-GACGACATCGACCACTTCGGCAAC-3′  
rpoB-R: 5’-GAACGGGTTGACCCGCGCGTACA-3′ 
Upon receipt of primers, a working stock solution was made up to a final concentration of 
10 pmol/µl (NHLS VIR0241, 2016). The primers were synthesized by the University of 
Cape Town, South Africa (NHLS VIR0241, 2016).  
The PCR reaction mixture (master mix) was made up as follows: each 20μl PCR mixture 
contained 10μl KapaTaq 2x Ready Mix with Mg2+ (Biosystems, Boston, USA), 1μl of the 





KapaTaq Ready Mix contained everything required for PCR except the primers and the 
template (0.05U/µl KapaTaq DNA polymerase, reaction buffer with Mg2+ and 0.4mM each 
dNTP) (Schleper et al., 1997). 
Addition of DNA 
Adding the template DNA was performed in a separate room. Two µl of template DNA 
was added to the 18µl PCR mixture and mixed with a pipette and placed into a 
thermocycler for amplification in a dedicated amplification room. The amplification 
parameters included an initial denaturation step at 95°C for 5 minutes, followed by 35 
cycles of denaturation at 95°C for 1 minute, annealing at 58°C for 45 seconds, and 
elongation at 72°C for 45 seconds, with a final elongation step at 72°C for 5 minutes. 
PCR cycling conditions: 
95°C for 5 minutes 
95°C for  1 min 
58°C for  45 sec         35 cycles 
72°C for 45 sec 
72°C for 5 min 
15°C for  hold 
Detection of PCR product 
Agarose (2%) gel electrophoresis was used to determine the presence or absence of 
PCR product and determine the size of the PCR product. 
Interpretation of PCR product 
Interpretation of the gel 
1. Presence of a single band size of 400 base pairs (bp) - positive for PCR product  







Figure 1: rpoB PCR of nine isolates (V17 to D18), a negative control (E18) and a positive control H37Rv 
(F18). All isolates had PCR product of 400bp thus MTB is detected and sent for sequencing. *MW VI = 
molecular weight marker VI (was used as a ladder), PCR = polymerase chain reaction,  
MTB = Mycobacterium tuberculosis, bp = base pairs 
 
2.3.3.2 DNA sequencing 
The rpoB sequencing of all amplified study isolate products was Sanger sequencing and 
was performed by Inqaba Biotechnical Industries (Pretoria, South Africa). PCR products 
underwent the chain termination method to sequence the segment that had been 
amplified (rpoB gene from codon 462 to 591). 
Procedure  
Once a single band of 400 bp PCR product was obtained, the PCR product as well as 
both forward and reverse primers were sent to Inqaba Biotechnical Industries for Sanger 
sequencing. At Inqaba, the PCR products were cleaned using Exonuclease I (New 
England Biolabs, Beverly, MA) and Shrimp Alkaline Phosphatase (New England Biolabs, 
Beverly, MA) mixture and incubated first at 37°C for 30 minutes then at 95°C for 5 
minutes. Sanger sequencing was performed with the ABI BigDye Terminator version 3.1 
cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) according to the 





products were cleaned with Zymo Research DNA sequencing clean-up kit (Zymo 
Research, Orange, CA) according to the manufacturer’s instructions. The cleaned 
products were analyzed on an ABI 3500XL Genetic Analyser (Applied Biosystems, Foster 
City, CA, USA) (Industries, 2015). 
Interpretation of DNA sequencing 
The DNA sequence data were analyzed and aligned manually against the reference 
sequence of H37Rv using DNAman software (LynnonBioSoft, Quebec, Canada); 
MFinder software was used to analyze any mismatches. MFinder software starts by 
scanning a user specified directory for matching forward and reverse complement AB1 
files. Base calling was done for both forward and reverse complement files using Phred 
with a cutoff parameter of 0.05. The forward and reverse complement files were then 
merged using a Biojava gapped aligner. Blastn was then used to find an alignment with 
H37Rv reference sequence. Mismatches in the alignment were recorded. A report for 
each of the sequence pairs was then generated indicating the position of the mismatches. 
All sequence results were analyzed for any sequence mismatch; if there was no 
nucleotide sequence mismatch then it was reported as “no mutation detected”. If there 
were any nucleotide mismatches the result was reported as “mutation detected” and 
further analyzed if the mismatch caused a codon change that led to an amino acid 
change. In the cases where mismatches were detected, the actual codon and amino acid 
change were reported. It was reported as a change from the original amino acid followed 
by codon number (according to the E. coli numbering scheme) and resultant amino acid 











Table 3: DNA sequences of two isolates (A14 and B14) aligned against the reference sequence H37Rv.  
H37v -  514 TTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGTCGGCGCTG    533 
A14   -  514 TTCATGGACCAGAACAACCCGCTGTCGGGGTTGACCCACAAGCGCCGACTGCAGGCGCTG    533 














A14 531 TCG CAG Serine (Ser) S Glutamine (Gln) Q S531Q 
B14 533 CTG CCG Leucine (Leu) L Proline (Pro) P L533P 
The sequence shown here is a segment of the RRDR (from codon 514 to 533). Isolate A14 underwent a 
double nucleotide polymorphism in codon 531; TCG was substituted with CAG causing an amino acid 
change from serine (S) to glutamine (Q) and the mutation is coded as S531Q. Isolate B14 underwent a 
single nucleotide polymorphism in codon 533; where CTG was substituted with CCG causing an amino 
acid change from leucine (L) to proline (P) and the mutation is coded as L533P. 
 
For Part1 of the study rpoB sequencing results were used as a gold standard test to 
determine whether the Xpert RIF results were false resistant or the LPA RIF results were 
false susceptible. 
Quality control 
PCR products were sequenced using bidirectional (i.e. forward and reverse) primers for 
maximum coverage and reproducibility of results. 
Controls were performed with every rpoB PCR and rpoB sequencing batch run as follows: 
1. H37Rv ATCC 27294 was used as the positive control for rpoB PCR and as a wild 
type control for sequencing  
2. Only master mix reagents were used as the blank control for rpoB PCR 
3. Ultra-pure water was used as the negative control for rpoB PCR 
4. Isolates that were LPA RIFR with MUT band present (high confidence rpoB 
mutations) were randomly selected and sequenced and were used as mutant 






2.3.4 Rifampicin minimum inhibitory concentration testing 
All MTB isolates that were selected for Part 2 of the study underwent MIC testing. 
Because the isolates were obtained during the same study period, MTB isolates that 
originated from Part 1 of the study that were determined to have a disputed rpoB mutation 
by sequencing were included in Part 2 of the study, and underwent MIC testing. 
MIC testing was performed using the MGIT 960 system and EpiCenter TB eXiST software 
with RIF concentrations of 0.0625, 0.125, 0.25, 0.5 and 1 μg/ml according to 
manufacturer’s instructions (Siddiqi SH, 2006, Springer et al., 2009). 
Procedure 
Preparation of Drug  
Rifampicin concentrations (Becton Dickinson Diagnostic Systems, Sparks, MD) were 
prepared according to manufacturer’s instructions. 
 For each isolate, six MGIT tubes were labeled as follows with their corresponding RIF 
concentrations: tube 1 (growth control tube), tube 2 (0.0625 µg/ml), tube 3 (0.125 µg/ml), 
tube 4 (0.25 µg/ml), tube 5 (0.5 µg/ml) and tube 6 (1.0 µg/ml). 100μl of the reconstituted 
RIF was added to the appropriately labeled corresponding MGIT tubes. No drug was 
added to the growth control tube. All MGIT tubes with antibiotic added are called test 
MGIT tubes. 
Preparation of inocula 
The primary MGIT culture was sub-cultured by transferring 0.5 ml of culture to a new 
MGIT tube (with supplement MGIT added) and incubated at 37°C in the automated MGIT 
instrument. Once the MGIT tube flagged positive for growth, “test” and “control” inocula 
were prepared from the tube when the growth unit (GU) was approximately 500 (day 1 or 
day 2 after flagging positive). A purity check was performed by streaking the MGIT culture 
onto a blood agar plate which was incubated for 48 hours at 37°C. 
Sub-culture MGIT tubes that were processed one or two days after flagging positive, were 
mixed well by vortexing and allowed to stand for one to two minutes to ensure that the 
larger clumps had settled. The upper layer of approximately 3.5 ml was aspirated into a 





that were processed between three and five days after flagging positive were mixed by 
vortexing and a 1:5 dilution was made in saline; this was used as the standard inoculum. 
Control inoculum was prepared by diluting the standard inoculum 1:100 in saline (100 µl 
standard inoculum + 9.9 ml saline). Then 0.5ml of the “control” inoculum was transferred 
to the “control MGIT tube” containing 0.8 ml of MGIT supplement. 
Addition of MTB and drug into MGIT tubes and incubation  
For the “test MGIT tubes”, 0.5 ml of the standard inoculum was transferred to each test 
tube containing 0.8 ml of MGIT supplement and respective RIF concentration with final 
RIF concentrations of 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml, 0.125 µg/ml and 0.0625 µg/ml. All 
MGIT tubes (control and test tubes) were inoculated at the same time and incubated at 
37°C in the BACTEC MGIT 960 instrument. 
Interpretation 
The interpretation was performed according to the manufacturer’s instructions. Briefly, an 
isolate was considered resistant if the time to positivity of the RIF containing tube was 
faster than that of the growth control tube or if the growth unit (GU) of the RIF containing 
tube was ≥ 100 when the growth control tube reached a GU of ≥ 400. Conversely, an 
isolate was considered susceptible when the growth unit of the RIF containing tube 
remained < 100 after the growth control tube reached a GU of ≥ 400. The MIC value was 
reported as the lowest concentration of the drug at which the isolate was susceptible 
(Figure 2). If tube 1.0 µg/ml has a GU of <100 and the remaining tubes (0.5, 0.25, 0.125 
and 0.0625 µg/ml) have GU >100 when a GU of ≥400 is reached in the growth control 
tube then the MIC is 1.0 µg/ml. If the GU is >100 in all test tubes (1.0, 0.5, 0.125, and 







Figure 2: MGIT MIC test for isolate Z7 showing six MGIT tubes; there is visible growth in tubes A) Growth 
control tube, B) TBeX 1 (0.0625µg/ml) and C) TBeX 2 (0.125µg/ml). There is no visible growth in tubes D) 
TBeX 3 (0.25 µg/ml), E) TBeX 4 (0.5 µg/ml) and F) TBeX 5 (1 µg/ml). Tubes A, B, and C had growth units of 
>400 reading from the MGIT instrument and tubes D, E, and F had growth units of zero. The lowest 
concentration at which the growth unit was <100 when tube A (growth control) had growth unit just 
exceeding 400 is considered the MIC value. The MIC value of isolate Z7 is reported as 0.25 µg/ml, i.e. tube 
D. 
*MIC = minimum inhibitory concentration, MGIT= Mycobacterium Growth Indicator Control Tube 
Quality control 
MGIT tube control 
Quality control was performed on new (lot numbers or shipment) MGIT tubes as per 
manufacturer’s instructions where H37Rv ATCC 27294 was used as the positive control. 
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Rifampicin drug control 
Quality control was performed on new (lot numbers or shipment) antibiotic reagents as 
follows: 
1. H37Rv was used as a susceptible control with an expected MIC value of 
≤0.0625µg/ml. 
2. Randomly selected isolates with known mutations (D516V, H526Y and S531L) that 
confer high level RIF resistance were used as resistant controls. 
3. Randomly selected isolates whose sequencing revealed no rpoB mutations were 
included as RIF susceptible controls (expected MIC ≤ 0.0625ug/ml). 
Details of reagent, lot number and expiry date were recorded and controlled before being 




This study received ethical approval from the Human Research Ethics Committee of the 
Faculty of Health Sciences at the University of Cape Town (HREC REF: 737/2014). 
 
2.5 Data recording and analysis 
Part 1 of the Study 
Xpert parameter results of cases and comparator group were recorded on an MS Excel 
spreadsheet.  Xpert parameters were used to calculate sensitivity, specificity, positive 
predicative value (PPV) and negative predictive values (NPV) and predict a false Xpert 








Table 4: Calculations of sensitivity, specificity, positive predictive value and negative predicative values 
False RIFR by Xpert Not false RIFR (True RIFR) by  Xpert  
Positive Parameter                                   A Positive parameter                                B 
Negative parameter                                 C Negative parameter                              D 
Sensitivity   = A/(A+C)                                                        Specificity =    D/(D+B) 
PPV = A/(A+B)                                                                      NPV =  D/(D+C) 
*RIFR = rifampicin resistant, PPV = positive predictive value, NPV = negative predictive value 
The LPA probe pattern for RIF was recorded for both cases and comparator group. The 
original interpretation and repeat interpretation of the routine LPA by investigators was 
also recorded and compared. The interpretation and probe pattern of the repeat LPA was 
also recorded and compared to the routine and repeat interpretation of the original LPA. 
Stata version 13.1 was used to obtain continuous Poisson regression to determine the 
probability of false RIFR by Xpert with regards to Xpert parameters and this was indicated 
in incidence rate ratio (IRR) with 95 % confidence intervals (CI), among isolates with 
discordant RIFR results. 
The sequencing result was used to determine whether the discordance was due to false 
RIFR by Xpert or false RIFS by LPA. If sequencing detected no mutation, the overall result 
was categorized as “false RIFR t by Xpert”. If sequencing detected an rpoB mutation within 
the RRDR, the overall result for the patient was “false RIFS by LPA”. 
For Part 1 and Part 2 of the Study 
Sequencing results were recorded as follows; 
• “No mutation detected” was recorded if there was no mutation detected within the 
sequenced rpoB gene which covered the RRDR 
• If a mutation was detected in the sequenced rpoB gene, the following were 
recorded; 
o The nucleotide polymorphism and/or deletion (from wild type nucleotide/s 
to mutant nucleotide/s),  
o Codon position number where the mutation occurred,  





o A mutation was abbreviated with original amino acid abbreviation followed 
by codon position number followed by substitute amino acid abbreviation  
o The mutation detected was compared to the Xpert probes and LPA probe 
bands pattern 
MIC results of both cases and comparator group were recorded. MIC value of ≤0.0625 
µg/ml was considered RIFS, MIC value >0.0625 and ≤1.0 µg/ml was considered low level 
RIFR and MIC of >1.0 µg/ml was considered high level RIFR. 
Excel was used to graphically determine MIC distribution among the miscellaneous rpoB 





































3.1 Part 1. Discordant Xpert RIFR and LPA RIFS 
From January 2014 to November 2015 there were 210,378 samples processed for Xpert 
at both GPT and GSH laboratories. Xpert detected MTB complex in 27,940 (13.3%) 
specimens and RIF resistance in 1542 (5.5%); this excludes duplicate specimens, i.e., 
more than one specimen per patient. 
For those patients with a RIFR by Xpert, the LPA result on the subsequent 2nd specimen 
for each patient was reported as RIFR in 1436 (93.1%) and as RIFS (i.e. discordant) for 
106 (6.9%) (Figure 1). rpoB DNA sequencing was performed on the discordant 106 
isolates of which 101 (95.3%) had sequencing results available.  Sequencing results were 
not obtained for five (4.7%) isolates due to the cultures being contaminated with other 
bacteria (n=3) or with NTM (n=2). The bacterial contamination was confirmed by the 
presence of bacterial growth on 2% blood agar. The presence of NTM was confirmed by 
the GenoType CM (common mycobacteria) LPA (HAIN, Lifescience, Nehren, Germany), 
which detects MTB complex as well as various non-tuberculous mycobacteria in addition 
to MTB. 
Of the 101 MTB isolates with DNA sequencing results available, a total of 78 (77.2%) had 
no mutation detected and these were categorized as “false RIFR by Xpert”. DNA 
sequencing detected a mutation in the RRDR of the rpoB gene in 23 (22.8%) isolates and 
these were categorized as “false RIFS by LPA”. For the latter group, the probe involved 
in the resistance detected by Xpert corresponded with the rpoB mutation detected by 




































Figure 1: The number of patients with discordant Xpert (RIFR) and LPA (RIFS) results and the proportions 
with mutations not detected (false Xpert) and mutations detected (false LPA) by sequencing. 
*MTB = Mycobacterium tuberculosis, RIFR = Rifampicin resistant, RIFS = Rifampicin susceptible, LPA = Line 
probe assay 
Xpert MTB detected  
n = 27,940 
Xpert RIFR 
n = 1,542 (5.5%) 
Xpert performed   
n = 210,378 
Sequencing results 
available 
 n = 101 (95.3%) 
LPA  
RIFS  
n = 106 (6.9%) 
LPA  
RIFR  
n = 1,436 (93.1%) 
No sequencing results 
available 
n = 5 (4.7%) 
(Contaminated) 
No mutation detected 
(False RIFR by Xpert) 
n = 78 (77.2%) 
Mutation detected 
(False RIFS by LPA) 
n = 23 (22.8%) 
Xpert parameter available 
(False RIFR by Xpert) 





3.1.1 False RIFR by Xpert (n=78) 
Of the 78 cases with false RIFR by Xpert (no mutation detected by sequencing), 76 
(97.4%) had Xpert parameter values available. The parameter values of the remaining 
two could not be obtained because the parameter values were not available on the LIS 
and readouts had not been archived. Xpert parameters were available for the entire 
control group of 1436 patients that had concordant RIFR results for Xpert and LPA. 
The total number of samples with RIFR results by Xpert during the study period for which 
Xpert parameters were available was 1512; this comprised 1436 true RIFR (the 
comparator group of patients with concordant Xpert and LPA results (controls)) plus 76 
false RIFR cases by Xpert (cases). 
The following Xpert parameters were compared: 
 
1. Probe delay versus probe dropout 
We assessed the value of probe delay and probe dropout in identifying false RIFR results. 
Probe delay (ΔCt max >4) occurred in 56/76 (73.7%) cases compared with 104/1436 
(7.2%) controls (p <0.0001). Probe dropout occurred in 20/76 (26.3%) cases compared 
with 1332/1436 (92.8%) in the control group (p <0.0001) (Table 1). 
Table 1: Accuracy of probe delay (∆Ct max > 4) vs. probe dropout for detecting a false RIFR result  
Xpert RIFR parameter 
True RIFR by 
Xpert  
n (%) 





Probe delay (∆Ct max > 4) 
 





Probe dropout 1332 (92.8) 20 (26.3) 1352 (89.4) 
















Probe delay ∆Ct 




73.7 92.8 35 98.5 
RIFR = Rifampicin resistant, ∆Ct = Delta cycle threshold maximum, IRR = Incident rate ratio, CI = Confidence 





Probe delay was a significant predictor of false RIFR by Xpert; an Xpert RIFR result that is 
due to probe delay was 23.66 more likely to be false RIFR than an Xpert RIFR result that 
is due to a probe dropout (95%CI: 14.59 - 38.78) (Table 1). 
 
2. A probe delay value (delta Ct max) of between 4.1 and 4.9 
We assessed the value of Ct max between 4.1 and 4.9 for identifying false RIFR. Of the 
1512 cases with RIFR by Xpert, 62 (4.1%) had resistance determined by probe delay with 
a ∆Ct max value between 4.1 and 4.9. The remaining 1450 (95.9%) Xpert RIFR cases 
had probe dropout or probe delay with Ct max above 5 (Table 2). 
Of the 1436 controls, 20 (1.4%) had a ∆Ct max value between 4.1 and 4.9 compared with 
the cases where 42/76 (55.3%) had a ∆Ct max of 4.1-4.9 (p <0.0001). 
 
Table 2: Accuracy of probe delay of ∆Ct max 4.1 - 4.9 vs. probe delay ∆Ct max ≥5 or probe 
dropout for detecting a false RIFR result 
Xpert RIFR parameter 
True RIFR by Xpert 
n (%) 





Probe delay ∆Ct max 4.1 - 4.9 20 (1.4) 42 (55.3) 62 (4.1) 
Probe delay ∆Ct max ≥ 5 or 
probe dropout 
1416 (98.6) 34 (44.7) 1450 (95.9) 
Total 1436 (100) 76 (100) 1512 (100) 
 









55.3 98.6 67.7 97.7 
RIFR = Rifampicin resistant, ∆Ct = Delta cycle threshold maximum, IRR = Incident rate ratio, CI = 
Confidence interval, PPV = Positive predictive value, NPV = Negative predictive value 
Probe delay with ∆Ct max value between 4.1 and 4.9 was a significant predictor of false 





between 4.1 and 4.9 was 28.89 times more likely to be false RIFR than an Xpert result of 
RIFR that where there was probe dropout or a probe delay with a ∆Ct max value ≥ 5 (Table 
2). 
3. Bacterial load (quantitative) 
We assessed the value of MTB bacterial load in identifying false RIFR results. A total of 
239 (15.8%) patients had RIFR results by Xpert with readouts of ‘Very Low’ bacterial load 
of which 47 were false RIFR making up 61.8% of the total cases that had false RIFR by 
Xpert (Table 3). 
 
Table 3: Comparison of proportion of patients with true vs. false Xpert RIFR stratified by 
bacterial load (as determined by Xpert); and the accuracy of a Very Low bacterial load result for 
detecting false RIFR 
Xpert Parameter   
True RIFR by Xpert 
n (%) 





Very Low 192 (13.4) 47 (61.8) 239 (15.8) 
Low 331 (23.0) 10 (13.2) 341 (22.5) 
Medium 479 (33.4) 9 (11.8) 488 (32.3) 
High 434 (30.2) 10 (13.2) 444 (29.4) 
Total 1436 (100) 76 (100) 1512 (100) 
RIFR = Rifampicin resistant, IRR = Incident rate ratio, CI = Confidence interval, PPV = Positive predictive 
value, NPV = Negative predictive value 
 
MTB bacterial load of Very Low occurred in 47//76 (61.8%) cases compared with 
192/1436 (13.4%) controls (p <0.0001) and VL MTB bacterial load is a significant 
predictor of false RIFR by Xpert.  
Xpert Very Low bacterial load parameter was a significant predictor of false RIFR 
compared to combined non-Very Low quantitative loads (Low, Medium or High). A RIFR 
result by Xpert with a Very Low bacterial load was 8.58 times more likely to be false RIFR 
Xpert RIFR 
parameters 
IRR 95% CI Sensitivity Specificity PPV NPV 
Very Low 8.58 
5.57 - 
13.21 





than a RIFR result with Non-Very Low bacterial load (IRR: 8.58, [95%CI: 5.57 – 13.21]) 
(Table 3). 
4. Xpert probes 
We assessed the value of delay of specific probes, as well as ‘double probe delay’ for 
identifying False RIFR. When compared to probe B; probes A, C, D and D+E were more 
likely to be involved in a false RIFR result while probe E was not a statistically significant 
predictor of false RIFR by Xpert. 
Double probe delay is defined as probe delay when two probes each have a Ct max 
value > 4 but the Ct max value of each of the remaining probes is ≤ 4. There were 12 
cases in the study period where RIFR was due to a double probe delay (all involved probes 
D & E) and all of these were false RIFR by Xpert. The control group had no RIFR results 
due to delay of more than one probe (all 3 Xpert results in the control group where RIF 
resistance involved more than one probe ([A+B] and [A+B+D]) were determined by drop-



















Table 4: Comparison of probes involved in Xpert RIFR and the probability of a result with these 
values being false RIFR 
Xpert probe 
True RIFR by Xpert 
n (%) 




A 71 (4.9) 7 (9.2) 78 (5.2) 
B 130 (9.1) 1 (1.3) 131 (8.6) 
C 9 (0.6) 1 (1.3) 10 (0.7) 
D 170 (11.8) 12 (15.8) 182 (12) 
D+E 0 (0) 12 (15.8) 12 (0.8) 
E 1053 (73.3) 43 (56.6) 1096 (72.5) 
A+B 2 (0.2) 0 (0) 2 (0.1) 
A+B+D 1 (0.1) 0 (0) 1 (0.1) 
Total 1436 (100) 76 (100) 1512 (100) 





 z  P >|z| 95% CI 
A  11.75    12.46 2.33    0.020 1.47 93.83 
C   13.09    18.02 1.87    0.062 .88 194.39 
D    8.63 8.94 2.08    0.037 1.14 65.65 
D+E  131.00    130.55 4.89    0.000 18.56 923.73 
E 5.14    5.18 1.62    0.104 .71 37.04 
A+B .00 .00 -7.82 0.000 6.44e-06 .00 
A+B+D .00 .00 -6.77 0.000 4.44e-06 .00 
B (reference) 1 .001 1 0.000 .001 .054 
RIFR = Rifampicin resistant   IRR: Incident rate ratio   CI = Confidence interval 
5.  Combination of parameters: Very Low bacterial load plus probe delay 
A total of 67 RIFR results by Xpert had both a probe delay (∆Ct max > 4) and a Very Low 
bacterial load. Of these, 43 (64.2%) results were false RIFR. Furthermore, in 42/67 
(62.7%) results with Very Low bacterial load the ∆Ct max value was between 4.1 and 4.9 
and 36 (85.7%) were false RIFR by Xpert (Table 5). This is in contrast with only 6 controls 










Table 5: Combinations of bacterial load and probe delay for assessing the accuracy of a RIFR 










Sens Spec PPV NPV 
VL + ∆Ct > 4 24 (35.8) 43 (64.2) 67 (100) 56.6 98.3 64.2 97.7 
Non (VL + ∆Ct > 4) 1412 (97.7) 33 (2.3) 1445 (100)     
VL + ∆Ct 4.1 - 4.9 6 (14.3) 36 (85.7) 42 (100) 47.4 99.6 85.7 97.3 
Non (VL + ∆Ct 4.1 - 4.9) 1430 (97.3) 40 (2.7) 1470 (100)     
VL + ∆Ct ≥ 5 24 (77.4) 7 (22.6) 31 (100) 29.2 98.3 22.6 95.3 
Non (VL + ∆Ct ≥ 5) 1412 (95.3) 69 (4.7) 1481 (100)         
RIFR = Rifampicin resistant, Sens = Sensitivity, Spec = Specificity, PPV = Positive predictive value, NPV = 
Negative predictive value, VL = Very low bacterial load, ∆Ct = Delta cycle threshold maximum 
The PPV of VL and ∆Ct max >4 is 64.2% and PPV of VL and ∆Ct max between 4.1 and 
4.9 is 85.7 with NPV of 97.7% and 97.3% respectively. 
6. Ct max 4.1 - 4.9 versus Very Low bacterial load 
When comparing the parameters Very Low bacterial load and Ct max between 4.1 and 
4.9 to each other and to other parameters, Ct max 4.1 - 4.9 (IRR: 15.7 [95% CI: 9.73 – 
25.34]) was a stronger predictor of false RIFR than Very Low bacterial load (IRR: 2.97 
[95% CI: 1.78 – 4.93]) (Table 6). 
Table 6: Comparison of Xpert RIFR parameters Very Low bacterial load and ∆Ct max 4.1 - 4.9 in 
predicting false RIFR 
Xpert parameter IRR Robust Std. Err. Z P >|z|  95% CI 
VL 2.97 0.77 4.19 0.000 1.78 4.93 
∆Ct 4.1 - 4.9 15.70 3.83 11.28 0.000 9.73 25.34 
_cons .019 .003 -21.18 0.000 .012 .027 
RIFR = Rifampicin resistant, VL = Very low bacterial load, ∆Ct = Delta cycle threshold maximum 









3.1.2 False RIFS results by LPA (n=23)  
Of the discordant isolates (Xpert RIFR and LPA RIFS) that had rpoB sequencing results 
available (n=101), 23 (22.8%) had a mutation detected by sequencing and were thus 
classified as false RIFS by LPA. All the mutations detected by sequencing lie within the 
RRDR of the rpoB gene and thus would be expected to be detected by the LPA. In all 23 
cases, the Xpert probe that failed to hybridize covered the region where the identified 























Table 7: List of 23 isolates that had false RIFS by LPA and true RIFR by Xpert showing Xpert probe 
involved in resistance corresponding with the rpoB mutation detected by sequencing  







U16 R A S L511P 
L R A S L511P 
H14 R D S H526L 
J R E S L533P 
P5 R E S L533P 
Q10 R E S L533P 
A17 R A S L511P 
Q2 R A S L511P 
E R E S L533P 
W R E S L533P 
O2 R A S L511P 
F4 R B S D516Y 
N R D S H526L 
F6 R D S H526N 
B R D S H526N 
S5 R E S H531L 
L2 R E S S531L 
Q15 R E S L533P 
O5 R D S H526N 
D6 R E S L533P 
Z3 R A S L511P 
A R A S L511P 
M15 R D S H526N 







The causes of false RIFS results by LPA were grouped as follows (Table 8): 
i. Technical error 
There were 11 cases where on further examination by study investigators, the 
routine LPA result was doubtful and a technical error causing the discordance for 
RIF between Xpert and LPA was deemed likely. These were further divided into 
questionable interpretation (n=6) or procedure error (n=5). 
a. Questionable interpretation (Figure 2) 
Six tests (U16, H14, P5, Q10, A17 and Q2) were interpreted as RIFS during routine 
reporting of the LPA. However, on examination by the study investigators, it was 
found that the patterns on both routine and repeat LPA strips was not clearly a wild 
type pattern and interpretation of this LPA result for RIF was deemed inconclusive. 
The original LPA strip was obtained and re-examined by the study investigators, 
who were blinded to the repeat LPA result at this point. It was noted that for all six 
cases, all wild type (WT) bands for rpoB were present (darker than the AC band) 
and there was no mutation band (MUT) present, in keeping with an interpretation 
of “susceptible” (as was done routinely). However, it was also noted that one WT 
band was lighter than adjacent WT bands for rpoB in the strip, even though it was 
the same intensity as the AC band in the strip. This lighter rpoB WT band 
corresponded to the mutation detected by sequencing. The LPA was repeated by 
the study investigator and the same pattern was observed, where the involved WT 
band was equal in intensity or more intense than the corresponding AC band; thus, 
interpretation would also be as susceptible, according to the package insert. 
Overall, the investigators assessed the LPA pattern for RIF as inconclusive and 
would recommend repeat testing (Table 8). 
b. Procedure error 
Five study isolates (L, J, E, D6 and M15) showed a susceptible pattern on the 
original LPA (presence of all WT bands and no MUT bands). The study 
investigators agreed with the interpretation of this. However, on repeat LPA testing, 
the rpoB pattern changed. The repeat LPA pattern had one WT band for rpoB 





of the absent WT band corresponded with the mutation that was detected by 
sequencing. Thus, an error in procedure or isolate mix-up had presumably 
occurred causing the routine LPA’s false RIFS result and discordance between 












Figure 2: “DNA strip” of the LPA showing the formation of bands where hybridization had occurred 
between amplicons from the isolate and the probe. Since the WT2 band is darker in intensity than the AC 
band, it is interpreted according to package insert as present, and the overall result as susceptible to 
rifampicin since all rpoB WT bands are present and there are no MUT bands. However, DNA sequencing 
detected L511P in this case which corresponds to absent rpoB WT2. The intensity of the WT2 band is not 
equal to that of the other rpoB WT bands, resulting in what we term “questionable interpretation”. 

















The WT2 band (band no. 5) is lighter in intensity than the 
adjacent WT bands but darker in intensity than the AC band. 
 
AC band 

































ng result   
Questionable interpretation (change in interpretation)  
U16, 
A17, Q2 
All WT bands 
present, no 
MUT bands. 
WT2 band is as 
strong as AC 
band  
Susceptible  Inconclusive 
rpoB WT2 




same LPA strip 
All WT bands 
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MUT bands. 
WT2 band is 
as strong as 
AC band but is 
lighter than 
other WT 
bands on strip 









H14 All WT bands 
present, no 
MUT bands. 
WT7 band is as 










same LPA strip 
All WT bands 
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MUT bands. 
WT7 band is 
as strong as 
AC band but is 
lighter than 
other WT 
bands on strip 










All WT bands 
present, no 
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same LPA strip 
All WT bands 
present, no 
MUT bands. 
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other WT 
bands in LPA 
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Procedure error (change in rpoB pattern on repeat testing)  
L  All WT bands 
present, no 
MUT bands. 



















strong as AC 
band  
bands on 
same LPA strip 
clearly absent; 
no MUT bands 
M15 All WT bands 
present, no 
MUT bands. 
WT7 band is as 
strong as AC 
band 
Susceptible  Susceptible  WT7 is clearly 
absent; no 
MUT bands  
Resistant  H526N 





WT8 as strong 





WT8 band is 
clearly absent; 




RIF = Rifampicin, RIFS = Rifampicin susceptible, LPA = Line probe assay, WT = Wild type, AC = Amplification 
control, MUT = mutation 
 
ii. Mixed infection  
There were six cases that fit the study definition of mixed infection. 
Three of these cases were deemed to have mixed infection based on the LPA indicating 
heteroresistance. The remaining three cases were deemed to have mixed infection on 
the basis of results of sequencing that was performed on more than one isolate from the 
same patient (Table 9). (Specimen/isolate mix-up could also be the cause of discordance 
for these three isolates). 
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present; no 




rpoB WT7 band 
is lighter than 
other rpoB WT 








All WT bands 
present; no 
MUT bands  
Susceptible Susceptible All WT 
bands 
present, no 
MUT bands  
Susceptible H526N 
RIF = Rifampicin, RIFS = Rifampicin susceptible, LPA = Line probe assay, WT = Wild type, AC = Amplification 
control, MUT = mutation 
 
iii. Laboratory mix up 
There were two isolates implicated in a laboratory mix up. Both isolates involved had rpoB 
mutation L531L detected by rpoB sequencing. In both cases, the routine LPA had all rpoB 
WT bands present and no rpoB MUT probe bands and was correctly interpreted as RIFS 
by routine testing. However, after repeating the LPA on each isolate the rpoB WT8 band 
was clearly absent plus there was a clear MUT3 band present.  On further examination 
of each of the LPA batches that included the “case patients’’’ LPA strips that had been 
processed in the routine laboratory, it was noted that for each case, there was an LPA 
pattern from an isolate that belonged to a different patient (“non-case patient”) with the 
same rpoB (and INH) banding pattern as the repeated LPAs (absent rpoB WT8 plus MUT 
3 band). In each case, the LPA strip of the non-case patient’s isolate was located 
immediately adjacent to the LPA strip of the study case. It was determined that a mix up 
(swap) during the routine processing of the LPA batch in the routine laboratory had 
occurred; most likely during DNA extraction. When the LPA was repeated, the aliquot for 
DNA extraction was taken from the MGIT tube of the correct patient (name and laboratory 
number were checked). On searching the Laboratory Information System, results of RIF-
susceptible by either Xpert or LPA on other specimens submitted within 7 days of the 





amended and the clinicians involved were informed of the correct results. The relevant 
laboratory was informed about the laboratory mix up and corrective actions were taken. 
 
iv. Indeterminate  
There were four isolates for which all LPA rpoB WT band intensities appeared stronger 
than that of the AC band on the routine LPA. These were thus routinely interpreted and 
reported as RIFS. On repeating of the LPA, the pattern remained unchanged. Sequencing 
of the isolates on which the LPA was performed revealed a mutation (which matches the 
probe implicated in resistance by Xpert). Mixed infection could not be excluded for these 
patients as no repeat samples were submitted for culture and DST (which would include 
routine Xpert and LPA). In addition, mix up of specimens / isolates could not be ruled out 


























































A, Z3 All WT bands 
present; no 
MUT bands  




Susceptible  L511P 
O5 All WT bands 
present; no 












Q15 All WT bands 
present; no 


























3.2 Part 2. Discordant LPA RIFR and MGIT RIFS 
During the six-month study period the LPA detected RIF resistance in 1502 patients, of 
which 169 (11.3%) had a “miscellaneous rpoB mutation”. In addition, a further 21 isolates 
were selected from “Part 1” of the study, where sequencing confirmed that the rpoB 
mutation was not one of the high level / high confidence rpoB mutations (not one of S531L 
/ H526Y / H526D / D516V). All of the isolates underwent RIF MIC testing. 
A total of 178 isolates had both MIC and rpoB sequencing results. There were 12 
excluded isolates overall (one from Part 1 and 11 from Part 2 of the study) (Figure 3). 
Sequencing results could not be obtained for seven isolates because the cultures were 
contaminated with other bacteria. MIC could not be performed on five isolates due to loss 
of viability (n=3 isolates with mutations H526P, D516Y, L533P) and contamination (n=2 
isolates with mutations H526P, H526L). 
Isolates that were sequenced and their MIC distribution appear in Table 11. Of the 178 
isolates with MIC results, 140 (78.7%) had an MIC ≤1 µg/ml (low-level RIFR or RIFS).  
Fifteen isolates were used as reproducibility controls for rpoB sequencing and as quality 








































Figure 3: Origin of isolates analyzed in Part 2 of the study. All isolates were proven to have rpoB mutations 
other than the 4 most commonly encountered (high confidence) rpoB mutations by rpoB sequencing. A 
total of 178 were included in the analysis where both sequencing and MIC results were available.  
*MIC = minimum inhibitory concentration, LPA = line probe assay, RIFR = rifampicin resistant 
 
 
Concordant Xpert RIFR and 
LPA RIFR  
n = 1502  
Part 2 of the Study 
“Miscellaneous mutations” as identified by LPA 
pattern of absent rpoB WT band and absent rpoB 
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n = 169  
Sequencing result 
not available   
n = 7 
Sequencing result 
available  
n = 162 
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n = 4 
MIC  
performed 
n = 158 
“rpoB mutation that is not one of the high 




n = 1 
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n = 20 
Total MIC and sequencing 
results available 
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Discordant True RIFR by Xpert 
and False RIFS by LPA 
n = 23 
Part 1 of the Study 
MIC ≤ 1 µg/ml 





Table 11: Relationship between rpoB mutations and MIC values (MGIT 960 EpiCenter) 
 












≤0.0625 0.125 0.25 0.5 1 >1.0 Total 
L511P 23 27 3 0 0 0 53 
H526N 6 10 3 0 0 0 19 
L533P 0 2 10 12 3 0 27 
D516Y 0 0 10 15 4 1 30 
H526L 0 0 0 1 6 4 11 
S531W 0 0 0 0 0 4 4 
D516F 0 0 0 0 0 5 5 
D516G 1 0 0 0 0 0 1 
Q513P 0 0 0 0 0 3 3 
Q513K 0 0 0 0 0 2 2 
S522L 0 0 0 0 0 2 2 
H526R 0 0 0 0 0 1 1 
S531C 1 0 0 0 0 0 1 
S531F 0 0 0 0 0 1 1 
S531Q 0 0 0 0 0 1 1 
L511P/D549E 0 1 0 0 0 0 1 
D516G/I572M  0 0 0 0 0 1 1 
H526N/S531W 0 0 0 0 0 1 1 
Q510L/D516Y 0 0 0 0 0 1 1 
D516Y/I572M 0 0 0 0 0 1 1 
D516G/L533P 0 0 0 0 0 1 1 
L511P/M515V/V581A 0 0 0 0 1 0 1 
del 518 0 0 0 0 0 1 1 
del517/518 0 0 0 1 0 0 1 
del 514/515 0 0 0 0 0 1 1 
del 514/515/516 0 0 0 0 0 3 3 
del 515/516/517 0 0 0 0 0 1 1 
del 513/514/515 0 0 0 0 0 1 1 
del 515/516/517/518 0 0 0 0 0 1 1 
del 511/512/513/514 0 0 0 0 0 1 1 
Total 31 40 26 29 14 38 178 
MIC = minimum inhibitory concentration, MGIT = mycobacterial growth indicator tube, RIFS = Rifampicin 





L511P, H526N, L533P and D516Y accounted for 72.5% (n=129) of the total isolates with 
miscellaneous rpoB mutations that had sequence and MIC results (Figure 4). Of these 
129 isolates; only one (D516Y) was high level RIF resistance with an MIC>1.0 µg/ml. The 
remaining 128 (99.2%) had an MIC of ≤1 µg/ml; 99 (76.8%) had an MIC between 0.125 
and 1 µg/ml (low level RIF resistant) and 29 (22.5%) were RIF susceptible with an MIC 
≤0.0625 µg/ml (Figure 5). 
   
Figure 4: Proportion of rpoB mutations detected from LPA RIFR with absent rpoB WT and MUT bands 
pattern. Four mutations made up 72.5% of the isolates with miscellaneous mutations as detected by LPA. 
The remaining 27.5% isolates had 26 other different mutations. 


















Figure 5:  MIC distribution of isolates with the four most common miscellaneous rpoB mutations L511P, 
D516Y, H526N and L533P. *MIC = minimum inhibitory concentration 
 
The remaining 26 less common mutations occurred in 49 isolates of which 37 (75.5%) 
had an MIC > 1.0 µg/ml; seven (14.3%) had an MIC of 1.0 µg/ml and five (10.2%) had an 
MIC ≤ 0.5 µg/ml (Figure 6). Seventeen of the 26 less common miscellaneous mutations 
were either double mutations (7) or double deletions (10). Fourteen (82.4%) of 17 isolates 



































Figure 6: MIC distribution of the 26 less common miscellaneous rpoB mutations identified by LPA and 
DNA sequencing   *MIC = minimum inhibitory concentration 
 
Controls:  The MIC value of all isolates from the control group were within the expected 
MIC range; there were ten isolates with rpoB mutations that are known to confer high 
level RIF resistance which all had an MIC >1 µg/ml and five MTB (H37Rv) isolates with 
no rpoB mutation had an MIC ≤ 0.0625 µg/ml. These isolates were also used as 
reproducibility controls for rpoB PCR and rpoB sequencing; rpoB PCR and sequencing 






























































Isolate rpoB sequencing results Repeat rpoB sequencing  MIC results (µg/ml) 
1 D516V D516V >1.0 
2 D516V D516V >1.0 
3 H526D H526D >1.0 
4 H526 H526D >1.0 
5 H526Y H526Y >1.0 
6 H526Y H526Y >1.0 
7 S531L S531L >1.0 
8 S531L S531L >1.0 
9 S531L S531L >1.0 
10 S531L S531L >1.0 
11 No mutation detected (H37Rv) No mutation detected (H37Rv) ≤0.0625 
12 No mutation detected (H37Rv) No mutation detected (H37Rv) ≤0.0625 
13 No mutation detected (H37Rv) No mutation detected (H37Rv) ≤0.0625 
14 No mutation detected (H37Rv) No mutation detected (H37Rv) ≤0.0625 





CHAPTER 4  
DISCUSSION AND CONCLUSION 
4.1 DISCUSSION  
 
4.1.1 Part 1. Discordant Xpert RIFR and LPA RIFS 
In South Africa, the most common discordant scenario involving TB tests that are used in 
the routine National testing algorithm is when the Xpert MTB/RIF reports RIFR and the 
confirmatory LPA performed on the patient’s second sample reports RIFS. 
In Cape Town, we found that 6.9% (106) of the 1542 patients with RIFR results reported 
by Xpert had a discordant RIFS result by LPA which was lower than the 16.3% 
discordance reported in Johannesburg (Berhanu R, 2015). 
In our study the true RIF result was determined by sequencing the same isolate on which 
the (routine) LPA was performed. The study that was conducted in Johannesburg did not 
perform sequencing (Berhanu R, 2015). 
We showed that Xpert MTB/RIF parameters can be utilized to predict false RIFR results 
by Xpert. Xpert parameters have similarly been used to determine the specificity of  RIFR 
results by Xpert  in the study by Ocheretina et al (Ocheretina Oksana, 2016). 
 
4.1.1.1 False RIFR by Xpert (n=78) 
Seventy eight of the total discordant cases that had sequencing results (101) were 
deemed to be false RIFR by Xpert as sequencing did not detect an rpoB mutation in the 
RRDR. Xpert parameters such as the Ct value not only provide a semi quantitative 
measure of the bacterial load in a specimen (Hanrahan et al., 2014, Blakemore et al., 
2011, Helb et al., 2010) but can be utilized to predict RIF susceptibility discordance 
(Berhanu R, 2015), to determine a false RIFR result by Xpert in discordant cases 
(Ocheretina Oksana, 2016) and potentially may be used to remove a likely false RIFR 





We found that probe delay was a significant predictor of false RIFR by Xpert; an Xpert 
RIFR result that has been determined due to probe delay was 23.66 times more likely to 
be false RIFR than an Xpert RIFR result that is due to a probe dropout (95%CI: 14.59 - 
38.78). This finding is similar to the findings of Ocheretina et al, where 91% of false RIFR 
(10/11) had probe delay (Ocheretina Oksana, 2016), and Berhanu et al, where 
discordance was 12.74 times more likely to occur with Xpert RIFR results due to probe 
delay than due to dropout (Berhanu R, 2015). We further classified the probe delay into 
two groups: probe delay where the Ct max value was between 4.1 and 4.9 and probe 
delay with Ct max ≥5. Probe delay with ∆Ct max value between 4.1 and 4.9 was a 
significant predictor of false RIFR by Xpert. An Xpert MTB/RIF RIFR result due to probe 
delay where probe delay has a ∆Ct max value of between 4.1 and 4.9 is 28.89 times more 
likely to be false RIFR than an Xpert MTB/RIF RIFR result that is due to probe delay with 
a ∆Ct max value ≥ 5 or where RIFR is due to probe dropout. In the context of a RIFR result 
by Xpert, we recommend that the Xpert MTB/RIF RIFR result be changed to inconclusive 
and Xpert be repeated on a repeat specimen. 
An MTB bacterial load of “Very Low” is also a significant predictor of an Xpert false RIFR 
result. In our study 61.8% (47/76) of the false RIFR results by Xpert had a Very Low 
bacterial load. This is similar to the proportion of 54.5% (12/22) determined by Ocheretina 
et al where they recommend that all RIFR results by Xpert with a Very Low bacterial load 
must be confirmed by culture based DST prior to reporting the RIF result as resistant 
(Ocheretina Oksana, 2016). A RIFR result by Xpert with a Very Low bacterial load is 8.58 
times more likely to be false RIFR than a RIFR result with a Non-Very Low bacterial load. 
In the context of a discordant RIF result between Xpert and LPA, where there is drop-out 
or delay with a ∆Ct max value ≥5, a Very Low bacterial load on the Xpert read-out could 
be used to consider that the Xpert RIFR result is likely the false result and that the LPA is 
likely the true (RIFS) result. We would recommend that a provisional comment is added 
to the LPA report noting the discordance, suggesting that the LPA is the true RIF result, 
and requesting a repeat specimen for repeat Xpert testing. 
It might be prudent, in a low MDR prevalence setting, that when a RIFR result by Xpert 





the Xpert test on a second specimen) before excluding RIF from the treatment regimen. 
However, in a setting of relatively high RIF resistance prevalence such as South Africa, it 
would be costly to repeat Xpert testing for all RIFR results with a Very Low bacterial load. 
In our study, 15.8% of the total RIFR results had a Very Low bacterial load and 80.3% of 
these had concordant RIFR results by LPA. In addition, withholding all RIFR results with a 
Very Low bacterial load until RIF resistance is confirmed by the LPA would delay 
commencement of the patient on an appropriate TB regimen and negate the benefit of 
the Xpert. 
The number of probes involved in determining the RIFR result by Xpert can also be used 
to predict the true RIF susceptibility result. If RIFR result by Xpert is detected due to double 
probe delay (not drop-out) (specifically probes D and E), we strongly recommend the 
Xpert test is repeated on another sample prior to releasing the resistant result. In our 
study there were 12 RIFR results by Xpert due to double probe delay (probes D and E) 
and all were found to be false RIFR by Xpert. This finding is similar to that found in the 
study by Ocheretina et al (Ocheretina Oksana, 2016) where 6/12 false RIFR were due to 
double probe delay (also involving probes D and E). 
A combination of the above predictive Xpert MTB/RIF parameters can be used to further 
strengthen the predictive value of false RIFR by Xpert. A RIFR result by Xpert that is 
determined by probe delay where the Ct max is >4 and there is a Very Low bacterial 
load has a positive predictive value (PPV) of 64.2 % of being false. If RIFR is due to probe 
delay where the Ct max is between 4.1 and 4.9 and in addition there is a Very Low 
bacterial load, the PPV of a false result increases to 85.7%. 
The Xpert graphs (fluorescence of probes) were analyzed for any abnormal shape of the 
curve that may result from disrupted amplification. This could arise from an air bubble that 
may be introduced in the cartridge during sample processing or by a high level of 
fluorescent background (e.g. a very high load of AFB’s in an aspirate sample). When the 
Xpert graph is irregular or abnormal; the result should not be reported and a repeat test 
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Figure 1: A) Sample O5 graph showing the sigmoid shape that is expected for all probes that bind to wild 
type sequence, and the lack of binding and fluorescence that occurs with true RIF resistance (in this case 
due to a Ct value dropout in probe D); the RIFR result should be reported.   B) Sample graph with abrupt 
and distorted fluorescence of probes due to an air bubble in the cartridge; the RIFR result should not be 
reported and a repeat test is recommended. C) Sample T2 Xpert MTB/RIF graph showing a high level of 
fluorescent background due to high bacterial load. The normal sigmoid curve is absent. This RIFR result 





We recommend that laboratories performing Xpert MTB/RIF should have a dedicated 
person who reviews all Xpert RIFR results and checks the Xpert probe readouts for any 
Xpert parameters that may predict false RIFR prior to releasing results to clinician. 
In our practice, at the point of review of the Xpert MTB/RIF RIFR result, we change the 
automatically generated RIFR result to RIF inconclusive in all cases where the ∆Ct max 
value lies between 4.1 and 4.9, no matter the bacterial load value. We also change the 
resistant result to RIF inconclusive when RIF resistance is determined by the presence 
of a double probe delay. We add a comment stating that the RIF resistant result has been 
changed to RIF inconclusive as it is suspicious for false RIF resistance, and we request 
that a repeat specimen be submitted for repeat Xpert MTB/RIF testing. This occurs before 
the LPA has been processed and resulted. 
In a case of Xpert / LPA discordance (at the point of review of the LPA result), the Xpert 
parameters are again examined (to make sure that there are no parameters that would 
lead us to change the Xpert result to inconclusive); if there is a very low bacterial load, 
but the ∆Ct max value is ≥5 (or there is probe drop-out), we report the RIFS result by LPA 
and add a comment to the LPA report suggesting that the likely explanation of the 
discordance is possible false RIFR resistant result by Xpert, we suggest that the likely true 
result is the RIFS by LPA and we request a repeat specimen for repeat Xpert testing. 
 
4.1.1.2 False RIFS by LPA (23) 
Twenty three percent of isolates were deemed false RIFS by LPA as an rpoB mutation in 
the RRDR was detected. 
Out of 23, 11 LPA strips were false RIFS due to technical errors. Seven of the 11 had 
questionable interpretation where the routine LPA strip should have been interpreted as 
RIF inconclusive rather than RIFS. The routine interpretation of RIFS was made according 
to the package insert provided by the manufacturer where it states that “a probe band 
must be interpreted as being present if its intensity is equal to or stronger than that of the 
AC band for that strip. The probe band is interpreted as absent if its intensity is less than 





comparison is subjective and sometimes it is difficult to determine if a band is absent or 
present when the intensity of the AC band is very light. Upon re-reading the routine LPA 
it was found that the intensity of one rpoB WT band was as strong as the AC but was 
clearly lighter than the other rpoB WT bands and this WT with light intensity corresponds 
to the mutation detected by sequencing. The same reading error was made by the 
automated Genoscan scanner that is used routinely in the GPT laboratory (Figure 2). We 
suggest that the LPA manufacturer to amend the interpretation criteria and comparing 
intensity of an rpoB WT band should not only be against the intensity of AC band but also 











Figure 2: “DNA strip” of the LPA read by the automated Genoscan as susceptible to both RIF and INH. 
Since the WT2 band is darker in intensity than the AC band, it is interpreted according to package insert 
as present, and the overall result as susceptible to rifampicin since all rpoB WT bands are present and 
there are no MUT bands. However, DNA sequencing detected L511P in this case which corresponds to 
absent rpoB WT2. The intensity of the WT2 band is not equal to that of the other rpoB WT bands, resulting 







AC band rpoB WT2 band is as strong as the AC band but 











Figure 3: “DNA strip 5” of a wild type MTB strain (where DNA sequencing detected no mutation in the 
rpoB gene. All (rpoB, katG and inhA) WT bands are darker in intensity than the AC. In addition, all rpoB WT 
bands are of equal intensity to each other. The correct interpretation of this LPA pattern is susceptible to 
both rifampicin and isoniazid. 
*WT = wild type, MUT = mutation, LPA = Line probe assay, AC = Amplification control 
 
The remaining four of 11 LPAs were incorrectly reported as RIFS as there was an error 
that occurred during the routine procedure. The routinely processed LPA strips had 
clearly RIFS patterns (all rpoB WT bands were stronger in intensity than the AC band of 
the same strip and the rpoB WT bands were as strong as each other). However, on repeat 
testing of the same isolate, the LPA pattern was different: it was clearly RIFR with one 
rpoB WT band clearly absent or lighter than the AC band. The particular absent rpoB WT 
band corresponded to the mutation detected by sequencing for each case. Thus, we 
concluded that the change in the result could have been from a laboratory mix-up, or an 
error occurring during the procedure, which would include an error within the LPA kit itself. 
In 2013 the GenoType MTBDRplus version 1 LPA was updated to a newer version (2) in 
order to improve the intensity of some rpoB WT probes that were often light and difficult 
to interpret leading to unnecessary and costly repeat testing. In addition, the MUT probe 
for L533P was removed from the version 2 as it had been found to lead to discordant 
genotypic / phenotypic RIF results and was thought to be a less clinically significant rpoB 
mutation at the time (Van Deun et al., 2013). The four isolates were routinely processed 
using the earlier version 2; hence on three isolates the L533P mutation was not detected. 
Version 2 GenoType MTBDRplus was subsequently updated to incorporate the L533P 








absent rpoB WT7 and absent MUT bands on repeat of the LPA which is the expected 
pattern for this particular rpoB mutation; the absence of this pattern on the routinely 
performed LPA could be explained by the improvement of intensity of bands in the earlier 
version 2 resulted in a WT7 band appearing as strong as AC.  Laboratory mix up or 
heteroresistance however, cannot be excluded. The repeat LPA performed on the four 
isolates by the study investigator was performed with the newest version 2 LPA. 
There were six cases with mixed infection. Detection of mixed infection is challenging and 
it also depends on the laboratory methods used. DNA sequencing can detect 
heteroresistance by showing a dual peaks chromatogram pattern (Kumar et al., 2014), 
however phenotypic DST and even LPA have been regarded as superior to Sanger 
sequencing for the detection of heteroresistance (Folkvardsen et al., 2013). We did not 
detect dual peak chromatogram patterns in any of the sequencing results. 
Despite the limitations of determining whether mixed infection in TB cases is present, we 
deemed 3 of the cases of false RIFS by LPA as having probable mixed TB infection as 
we had results of Sanger sequencing for 2 sequential isolates for each case (sequencing 
was inadvertently performed on an isolate from a second specimen that had been 
submitted from the patient within a week of the index specimen being submitted). 
Whereas one sequencing result detected the presence of a mutation (thus classifying the 
case as false RIFS by LPA), the sequencing performed on the second isolate detected no 
rpoB mutation in the RRDR. Another possible cause of discordance of this group could 
be specimen mix-up. 
The remaining three cases with mixed infection were categorized as such as there was a 
heteroresistant pattern for INH on the routinely performed as well as the repeat LPA strips. 
One can report heteroresistance by the LPA for a drug when a MUT band as well as all 
WT bands are present. For RIF, each rpoB MUT band that is included in the LPA 
corresponds to a high level rpoB mutation (S531L, H526Y, H526D or D516V). Thus, when 
heteroresistance is visible for RIF on the LPA, it is due to presence of a high-level RIF 
mutation, in addition to presence of a susceptible strain. In the case of heteroresistance 
involving the presence of RIFS and RIFR due to a miscellaneous rpoB mutation, the LPA 





MUT band present. The current version of the LPA does not include MUT bands for 
sequences belonging to the disputed rpoB mutations. 
Two cases of false RIFS by LPA were erroneously reported as RIFS as they were involved 
in a laboratory isolate mix up that most likely occurred during DNA extraction, the first 
step of 3 in the LPA procedure. A definite laboratory mix up occurred but we were unable 
to determine the exact error. Possible errors that may have occurred are that the DNA 
strips may have been mislabeled or placed in the incorrect LPA tray wells or PCR 
amplicon tubes or MGIT tubes may have been switched around. 
It is important that all laboratory procedures are streamlined and quality controlled to limit 
any laboratory mix-ups of specimens / isolates.  At the time of reporting the LPA result it 
is important to ensure that the RIFS result by LPA is not discordant with any RIF result by 
Xpert on the patient. In the case of discordance, one of the easiest causes to rule out is 
laboratory mix up. Where a RIFR result by LPA is expected (to match resistance result of 
Xpert), the entire LPA batch should be checked to see if there are any other strips (usually 
but not always adjacent to the susceptible strip in question) that have a RIFR pattern and 
particularly if that pattern corresponds with the probe detecting a mutation in the patient’s 
Xpert result. 
There were four cases that could not be definitively categorized as either technical error, 
specimen / isolate mix-up or mixed infection. The repeat LPA patterns remained the same 
as the routine LPA patterns and the interpretation of RIFS remained. The rpoB WT bands 
were all present and their intensities were stronger than the AC band (and no WT band 
was lighter in intensity than the other WT bands).  Specimen mix up could not be ruled 
out and since there was only one specimen submitted from each patient mixed infection 
could not be ruled out either. 
Some possible causes of discordant Xpert / LPA results are pre-laboratory and laboratory 
specimen mix-up or laboratory contamination. Adhering to good laboratory practice by 
working aseptically and cleaning of working environment, following procedure according 
to the manufacturer’s instruction and processing negative and positive controls with each 
batch is important. If the control result is not the expected result (e.g., LPA negative 





repeated prior to releasing any result from that batch. False RIFS by LPA may occur if an 
isolate exhibiting a miscellaneous rpoB mutation is contaminated with a true RIFS isolate 
resulting in the LPA strip will show all rpoB WT bands and reported false RIFS. Laboratory 
mix-up or contamination can be minimized by ensuring there are continuous training and 
competency checks of technical staff and implementing internal control checks of each 
process regarding the particular assay. 
The findings of this study have assisted our laboratory in developing a guide that 
laboratorians in this lab as well as in other TB laboratories in the organization can use to 
deal with discordant RIF results. The guide is divided into sections starting with how to 
identify a possible false RIFR result by Xpert. It includes how to exclude false RIFS result 
by LPA and lastly how to deal with a discordant RIF result. The guide has been circulated 



















Table 1: Guideline for TB laboratories to investigate possible false RIFR by Xpert and discordance 
with a subsequent RIFS by LPA *Full guideline available as Appendix A 
1. All RIFR results by Xpert should be checked prior to releasing the result. During Xpert review 
check the Xpert parameters for a possible false RIFR result. 
a. Probe delay where the ∆Ct max value is between 4.1 and 4.9 
• Report RIF inconclusive, repeat Xpert on second specimen 
b. Double probe delay (specifically delayed hybridization of probes D and E) 
• Report RIF inconclusive, repeat Xpert on second specimen 
c. An abnormal graph fluorescence curve  
• Report RIF inconclusive, repeat Xpert on second specimen 
2. If a RIFS result by LPA is reported, but this is discordant with an already-reported Xpert result of 
RIFR 
a. Check the Xpert readout and graph (as point 1 above)  
b. If Very Low MTB bacterial load was detected by Xpert, then it is likely false RIFR by Xpert 
c. Note which probe is involved (Ct=0 or delay >4) in the Xpert RIFR result 
• If for example the RIFR result by Xpert was due to probe dropout or probe delay 
of probe D, it is expected that the LPA has an absent rpoB WT7 band. The LPA 
WT7 band may be equal or darker in intensity than the AC band (especially if the 
AC bands of most strips in the batch are very light) but intensity of WT7 should be 
compared to intensity of all the other rpoB WT bands. If it is lighter than the 
others rpoB WT bands it is possible that it should be interpreted as absent rather 
than present (and hence resistant rather than susceptible for RIF) 
d. Check LPA result again and repeat if indicated 
• Obtain the LPA strip if possible. If not possible, obtain a photo of the strip (in a case 
where Genoscan was in use). Look again at the intensity of all the rpoB WT bands. 
Although the LPA package insert states that comparison of intensity of the band is 
made only with the AC band, in some cases of false RIFS results by LPA, the AC band 
is particularly light, and the WT2 / WT7 band in particular is more intense than the 





bands in a case where Xpert has detected resistance due to probe delay / dropout 
in probes A / D respectively 
e. If there is no obvious questionable rpoB WT bands, consider repeating the LPA 
f. Batches of LPA should be checked for any indication of contamination; specimen / culture 
mix up i.e. laboratory contamination# I should be ruled out prior to reporting of any results 
3. All previous and current results of a patient should be checked prior to reporting results to 
clinicians; 
a. Actively look for all previous molecular (Xpert and LPA) results on the patient, as well as 
any phenotypic DST results 
b. Examine the probe patterns and graphs of each Xpert and LPA result to make sure no 
technical errors occurred 
c. Multiple specimens / isolates with repeatedly discordant results may be an indication of 
true mixed infection 
4. Repeat testing  
a. If interpretation of all performed tests seems correct according to the probe patterns 
expected, and the Xpert graphs look normal, repeat testing is recommended: 
b. LPA should be repeated as not always possible to repeat Xpert on the same specimen at 
the time of discordance and repeating the Xpert on culture may be considered 
c. If the Xpert parameters indicate likely false RIF resistance, the Xpert should be repeated on 
a second sample that should be submitted (a comment must be added to original Xpert 
report) 
d. If repeat testing gives the same result, further tests may be done, if available  
• Phenotypic DST (MGIT method most commonly available); the limitations of 
particularly liquid based phenotypic should be considered i.e. MGIT DST may miss 
disputed rpoB mutations that confer low level RIF resistance  
e. If the Xpert and LPA results are not altered after all results are checked, the isolate (on 








4.1.2 Part 2. Discordant genotypic / phenotypic results: Xpert /LPA RIFR and MGIT 
RIFS 
In selecting isolates to include in this part of the study, we termed all rpoB mutations other 
than the non-disputed (high confidence) rpoB mutations (D516V, H526Y, H526D and 
S531L) (Figure 4) as “miscellaneous rpoB mutations”. The isolates with miscellaneous 
rpoB mutations were selected based on the LPA pattern of absence of any rpoB WT band 
and absence of an rpoB MUT band. 
In this study we showed that the less common, “miscellaneous” mutations detected by 
the LPA accounted for 11.3% of RIF resistance in our setting. A similar proportion was 
found in strains from Bangladesh (13.1%) and Kinshasa (10.6%) (Van Deun et al., 2013, 
Van Deun et al., 2015). Our study was performed in two laboratories that render service 
to most of the Western Cape public health sectors and is therefore representative of the 
Western Cape strain population. Similar studies should be performed in other regions of 




































Figure 4: LPA strip patterns from isolates of MTB that harbour the 4 most common non-disputed (high 
confidence) rpoB mutations that confer high level RIF resistance. A) Isolate A harbours the D516V 
mutation (absent rpoB WT3&4 bands and presence of MUT1 band). B) Isolate B harbours the H526Y 
mutation (absent WT7 band and presence of MUT2A band).  C) Isolate C harbours the H526D mutation 
(absent rpoB WT7 band and presence of MUT2B band) D) Isolate D harbours the S531L mutation (absent 
rpoB WT8 band and presence of MUT3 band). Isolates harbouring these 4 mutations were not the subject 
of Part 2 of this study  
 *LPA = line probe assay, MTB = Mycobacterium tuberculosis, RIF = rifampicin WT = wild type probe, MUT 
= mutation probe 
In our study 140/178 (78.7%) isolates with miscellaneous rpoB mutations (n=158) or 
confirmed (previously described) disputed rpoB mutations (n=20) had MIC values ranging 
from ≤0.0625 µg/ml to 1.0 µg/ml. These would be reported as RIFS by MGIT DST. Only 




Isolate A: rpoB WT3&4 absent, 
MUT1 present (arrow) (D516V) 
Isolate B: rpoB WT7 absent, MUT2A 
present (arrow) (H526Y) 
Isolate C: rpoB WT7 absent, MUT2B 
present (arrow) (H526D) 
Isolate D: rpoB WT8 absent, 












DST. A laboratory based study in Johannesburg found that, of 51 isolates with 
miscellaneous rpoB mutations as determined by LPA pattern, 25 (49%) tested RIFR by 
MGIT DST, and the other 26 (51%) tested RIFS by MGIT DST. The latter would be 
expected to have low level rifampicin MICs or be susceptible to rifampicin (Beylis N, 
2012). 
 
L511P (miscellaneous mutations in codons spanning 510-511) 
Isolates that harbour the L511P mutation are identified on the LPA  as an absent rpoB 
WT2 probe with no corresponding MUT band (Figure 5). According to the GenoType 
MTBDRplus package insert, the rpoB WT2 region spans rpoB codons 510-513 and the 
most commonly encountered mutation in this regon is L511P (Hain-Lifescience, July 
2013). Twenty three (42.6%) had an MIC ≤0.0625 µg/ml (susceptible to RIF) and the 
remaining 31 (57.4%) had MICs ranging between 0.125 and 0.25 µg/ml (low level RIF 
resistance).  None of the isolates had an MIC above 1.0 µg/ml thus none would test RIFR 
by MGIT DST. Thus if the LPA determines RIFR by virtue of [WT2 absent, no MUT band] 
it can be assumed that in most cases it is due to L511P, and that in 42.6% of cases it 
translates to true RIFS (begging the question of whether RIFR should be routinely reported 
by the LPA (or perhaps whether this particular mutation should be reported at the point 
of reporting RIFR by LPA) and whether RIF should be included in the TB regimen) while 
in the remaining 57.4% it translates to low level RIF resistance where RIF at high doses 
may be added to the regimen (van Ingen et al., 2011).  Thus it must be determined 
whether this mutation should be reported on the final LPA laboratory report, along with 
implications for phenotypic DST and level of RIF resistance. RIF is the most effective TB 
drug, and these patients would be treated by MDR therapy as per national guidelines, 
and that this is less effective and more toxic, with current regimens. 
There is limited data on the clinical relevance of the L511P mutation but some 
observational studies indicate that patients infected with MTB that harbours this rpoB 
mutation fail standard TB regimens and require extended / drug resistant TB regimens 
(Williamson et al., 2012) or regimens that contain high dose RIF. This may imply that 
despite a low level RIF resistance or even a susceptible MIC level, standard regimens 





the clinical significance of such mutations and whether they should be reported to 
clinicians when they are detected by molecular tests. 
In addition to L511P, the LPA package insert lists E510H as a mutation that could be 
detected in this codon region; we did not detect this mutation in the 54 isolates tested 
though one isolate had double mutation of L511P and D549E (which is outside the 
RRDR). E510H has very rarely been described in clinical isolates. The E510H mutation 
has been reported in combination with D516Y in an isolate with MIC of 1.0 µg/ml (Andres 



















Figure 5: An MTB isolate that harbours L511P from patient X8. The LPA pattern shows that all the rpoB 
WT bands except WT2 are stronger in intensity than the AC band. WT2 is lighter in intensity than AC and 
the LPA is  thus interpreted as RIFR. The MIC was ≤0.0625 µg/ml which is lower than the critical 
concentration (1 µg/ml) used for MGIT and would thus test RIFS by MGIT DST; leading to a discordant 
genotypic / phenotypic RIF result. 
*WT = wild type probe, MUT = mutation probe, AC = Amplification control, RIFR = rifampicin resistant, RIFS 
= rifampicin susceptible, INHS = isoniazid susceptible, LPA = line probe assay MIC = minimum inhibitory 






rpoB WT2 band is lighter in intensity than the comparator AC band 
Interpretation: RIFR and INHS 
DNA sequencing result: L511P 






H526N, H526L and H526R (miscellaneousmutations detected in codons spanning 526-
529) 
There were 31 isolates with miscellaneous mutations as determined by the LPA in the 
region spanning codons 526-529 [LPA pattern of absent rpoB WT7 and absent MUT 
bands] (Figure 6). All isolates harboured a mutation in codon 526 of which 19 were 



















Figure 6: An LPA of an isolate from patient F6 showing absent rpoB WT7 probe and absent MUT bands, 
reported as RIFR. DNA sequencing showed H526N mutation and the MIC in this case was ≤0.0625 µg/ml 
which is lower than the critical concentration (1 µg/ml) thus would be expected to test RIFS by MGIT DST 
(and lead to a discordant genotypic / phenotpic RIF result). 
*WT = wild type probe, MUT = mutation probe, RIFR = rifampicin resistant, RIFS = rifampicin susceptible,  
INHS = isoniazid susceptible LPA= line probe assay, MIC= minimum inhibitory concentration, DST = drug 
susceptibility testing  
 
All isolates with H526N had an MIC ≤0.25 µg/ml:  6 had an MIC ≤0.0625 µg/ml ; 10 had 
an MIC of 0.125 µg/m and 3 had an MIC of 0.25 µg/ml. Our findings correlate with those 
of van Deun et al where 4/5 isolates with H526N were reported to confer low level RIF 
resistance and contrary to our finding one isolate was RIFR by MGIT DST at 1.0 µg/ml 





rpoB WT7 band is absent 
Interpretation: RIFR and INHS 
DNA sequencing result: H526N 






0.5 µg/ml (n=1) through 1.0 µg/ml (n=6) to >1.0 µg/ml (n=4). The MIC values were similar 
to other reports on isolates with H526L confering borderline RIF resistance (the term 
borderline is used for MTB isolates which are RIFS at 0.5 to 1.0 µg/ml using MGIT DST 
but RIFR at the same concentration by proportion method on solid agar) (Ocheretina et 
al., 2014, Van Deun et al., 2009). One isolate harbouring H526R had an MIC of >1.0 
µg/ml (Figure 5). 
In our study, all isolates with rpoB mutation H526N had an MIC value ≤0.25 µg/ml 
conferring low level rifampicn resistance. An MIC value of ≤1.0 µg/ml should be expected 
for all isolates harbouring the H526N mutation and if the laboratory could detect the actual 
amino acid / nucleotide change this result could be  communicated to the clinician with a 
comment suggesting low level RIF resistance for treatment regimen consideration. 
Sequencing is not available routinely and the LPA that is more readily available does not 
differentiate between different amino acid changes; hence all mutations in codon 526 
(besides H526Y and H526D) will appear with the LPA pattern of absent WT7 and absent 
MUT band . If future clinical studies deem it important to report low level RIFR mutations, 
it may be useful for future versions of the LPA to include sequences for the more common 










Figure 7: MIC value in isolates with mutations in codon 526. The majority (84%) of miscellaneous rpoB 
mutations in codon 526 translate to low level RIF resistance or RIFS by phenotypic testing. 
*MIC = minimum inhibitory concentration, RIFR = rifampicin resistant, RIFS = rifampicin susceptible 
 
In comparison with the LPA pattern of [WT2 absent, no MUT] where 98.1% of mutations 
in this study were due to L511P, LPA pattern of [WT7 absent, no MUT] can be due to one 
of 3 mutations which have variable MICs (Figure 7). However, 84% of them translate to 
a MGIT RIFS result. It is not possible for the LPA to differentiate between the disputed 
rpoB mutations that occur in codon 526, thus it is more difficult for the laboratory to 
comment on the level of MIC expected for mutations detected in this rpoB region. Further 
studies with more isolates would add value here. A mutation detected in this codon region 
by LPA should lead to confirmation by phenotypic DST, ideally by MIC testing. Again the 
clinical relevance of these mutations is unclear. Orchereina et al described four isolates 
with the H526L mutation with MICs ranging from 0.5 to 4 µg/ml (Ocheretina et al., 2014) 
and one isolate with 0.5 µg/ml (Williamson et al., 2012); all patients failed the standard 
TB regimen. Williamson et al described one isolate with mutation H526N with a low level 







Low level RIFR (0.125 ≤ MIC ≤1.0 µg/ml)





S533P, S531W, S531C, S531F and S531Q (miscellaneous mutations in codons 
spanning 530-533)  
There were 34 isolates with miscellaneous rpoB mutations as identified by the LPA with 
absent rpoB WT8 and absent MUT bands (Figure 8). According to the LPA package insert 
the mutations in this region span from codon 530 to 533. There were five different 
mutations detected by sequencing namely L533P (n=27 (79.4%)), S531W (n=4), S531C 
(n=1 ), S531F (n=1) and S531Q (n=1). The MIC values for all isolates with L533P 
mutation were ≤1 µg/ml (but >0.0625 µg/ml). These low level MIC values are similar to 
those determined in previous studies (Rigouts et al., 2013, Ho et al., 2013, Andres et al., 
2014) which reported MIC values ranging from 0.5 µg/ml (Andres et al., 2014) to 1.0 µg/ml 
(Ho et al., 2013). Rigouts et al showed that all tested isolates (n=14) with L533P were 
RIFS at 0.5 µg/ml and 1.0 µg/ml using MGIT DST but all tested RIFR at the same 
concentration using solid (LJ) DST (Rigouts et al., 2013). This finding is similar to ours 
where all the isolates with L533P tested RIFS at 1.0 µg/ml but we had 24 (88.9%) that 
were RIFS at 0.5 µg/ml. The one isolate with S531C had a RIFS MIC of ≤0.0625 µg/ml 
similar to that previously reported with MIC value ≤0.125 µg/ml (Berrada et al., 2016). The 
remaining six isolates with S531F, S531Q, S531W mutations all had an MIC >1.0 µg/ml 
(high level RIF resistance and would be expected to test RIFR by the MGIT DST method); 
these were previously reported to have an MIC of  >8 µg/ml (Berrada et al., 2016). 
In summary, of the 34 isolates that had the LPA pattern of [absent rpoB WT8 and absent 
MUT bands], 27 (79.4%) had low level RIF resistance by MIC testing, one was RIFS 
(MIC≤0.0625 µg/ml) and the remaining  6 (17.6%) had RIF MIC >1.0 µg/ml. All isolates 
with rpoB mutation L533P had an MIC value between 0.0625 µg/ml and ≤1 µg/ml, 
conferring low level RIF resistance. Since this mutation accounted for the majority (79.4 
%) of mutations detected by this LPA pattern, the laboratory reporting RIF resistance 
when this LPA pattern is detected could add a comment that in about 80% of cases, it 
translates to low level rifampicin resistance. Future versions of the LPA may consider 
including a MUT band for this particular mutation, should it be deemed clinically significant 

























Figure 8: LPA strip of an isolate from patient D6 showing absent rpoB WT8 and absent MUT bands which 
is reported as RIFR. DNA sequencing detected L533P. The MIC was 0.25µg/ml which is lower than the 
critical concentration (1µg/ml) and would be expected to test RIF susceptible by MGIT DST 
*WT = wild type probe, MUT = mutation probe, RIFR = rifampicin resistant, INHS = isoniazid susceptible,  
LPA = line probe assay, MIC = minimum inhibitory concentration, AC=Amplification control, MGIT = 
mycobaterium growth indicator tube, DST = drug susceptibility testing 
D516- / disputed mutations in codons 513 to 519 
There were 43 isolates with miscellaneous mutations identified by LPA with the pattern 
[absent rpoB WT3&4 and absent MUT bands] (Figure 9). This pattern corresponds to a 
region of the RRDR spanning from codon 513-519. D516Y was the most frequent 
mutation (n=30) detected by sequencing and 29 (96.7%) had an MIC between 0.25 and 
1 µg/ml. The distribution of MICs for the 29 isolates with D516Y was 0.25 µg/ml (n=10), 
through 0.5 µg/ml (n=15) to 1.0 µg/ml (n=4). The remaining isolate with D516Y had an 
MIC value above 1.0 µg/ml. The D516Y mutation has been reported previously to confer 
low level RIF resistance with MIC value between 0.25 µg/ml and 1.0 µg/ml (Van Deun et 




LPA MTBDRplus: rpoB WT8 probe is weaker in intensity than AC and is 
interpreted as absent (resistant to RIF) 
Interpretation: RIFR and INHS 
DNA sequencing: L533P 






From the remaining 13 isolates, five had D516F and seven had either double mutation or 
deletions of nucleotides in more than one codon. All of these 12 isolates had MICs of >1.0 
µg/ml. The D516F mutation has been reported previously to have MIC >1.0 µg/ml and 
isolates with either deletions of nucleotides or double mutation involving codon 516 have 
also been reported to have  MIC >1.0 µg/ml (Berrada et al., 2016) and thus lead to high 
level RIF resistance. 
There was only one isolate that harboured the D516G mutation and it had an MIC ≤0.0625 
µg/ml (susceptible). This particular mutation has previously been reported to confer low 
level RIF resistance with an MIC value 0.5 µg/ml  (Ho et al., 2013). 
Overall, of  the 43 MTB isolates with this particular LPA pattern, one D516G was RIFS; 
29 had low level RIFR MIC (all of which were D516Y) and 13 (30%) had high level RIFR 






















Figure 9: LPA strip of an isolate from patient F4 showing absent rpoB WT3&4 probes and absent MUT 
bands as well as absent katG WT probe and katG MUT1 probe present and  therefore reported as MDR. 
DNA sequencing showed D516Y mutation and MIC value was ≤0.5µg/ml which is lower than the critical 





Absent rpoB WT3&4 probes 
Interpretation:  RIFR 
DNA sequencing: D516Y 
MIC value =0.5µg/ml 
Absent katG WT probe 
and positive 
hybridization of katG 
MUT1 probe 
Interpretation:  Resistant 





*WT = wild type probe, MUT = mutation probe, RIFR = rifampicin INH = isoniazid, MDR = multi drug 
resistant, LPA= line probe assay, MIC= minimum inhibitory concentration, MGIT = mycobacterial growth 
indicator tube, DST = drug susceptibility testing 
 
Of the remaining 16 isolates that had miscellaneous rpoB mutations, the majority had an 
MIC >1.0 µg/ml (n=14) and two had MICs of 0.5 and 1.0 µg/ml. 
There were eight isolates that were identified by LPA as absent rpoB WT2&3 bands and 
absent MUT bands that by sequencing exhibited rpoB mutations Q513P (n=3), Q513 
(n=2), del511-514 (n=1) and del513-515 (n=1). All of these had MICs of >1.0 µg/ml and 
one isolate with a triple mutation L511P/M515V/V581A had an MIC of 1.0 µg/ml. 
There were two isolates identified by LPA as absent rpoB WT5&6 and absent MUT bands 
that exhibited the S522L rpoB mutation and had an MIC >1.0 µg/ml. Isolates with the 
S522L mutation have been reported to be resistant at 1.0 µg/ml using MGIT DST 
(Jamieson et al., 2014). 
One isolate had absent rpoB WT4 and absent MUT bands and exhibited the  deletion 
del517,518 with an MIC of 0.5 µg/ml. 
The remaining five isolates were  identified by LPA as absence of  two or more rpoB WTs 
and absent MUT bands: absent rpoB WT2,3&4 (mutations Q510L & D516Y);  absent 
rpoBWT3,4&8 (mutations D516G &L533P); absent rpoB WT3,4&5 (deletion del 515-518); 
absent rpoB WT4,5 (deletion del518) and absent rpoB WT7&8 (mutations H526N & 
L531W). 
Isolates with an LPA pattern of two or more absent rpoB WT bands and absent MUT 
bands all had an MIC ≥1.0 µg/ml. Although the exact same patterns/combinations of 
double mutation have not been described elsewhere, isolates with other double rpoB 
mutations have been shown to have variable MICs (Jamieson et al., 2014). 
In our setting most (93.3%) of isolates identified by the LPA as miscellaneous rpoB 
mutations with 2 or more absent rpoB WT bands and no MUT bands had an MIC 
>1.0µg/ml. The one exception was an LPA pattern with absent rpoB WT3&4 bands (and 





helpful for the laboratory to report that the mutations detected almost always confer high 
level RIF resistance. 
Since the proportion of miscellaneous rpoB mutations is 11.3% and 78.7% of these have 
MICs below 1 µg/ml, we can estimate that 9% of all RIF resistance detected by molecular 
tests in our setting will not result in high level RIF resistance, and be expected to give a 
discordant susceptible result with phenotypic DST using the MGIT method. Some 
questions remain unanswered and require further study, including the clinical significance 
of each of these miscellaneous rpoB mutations, whether they should be reported 
routinely, at the point of diagnostic testing (i.e. when the LPA indicates that it is not a high 
confidence RIF resistant mutation (by virtue of there being an absent MUT band when 
there is absence of a WT band)), and what TB regimen is best suited to the isolate – 
specifically whether rifampicin should be included in the regimen and if so, at what dose. 
Limitations of the study 
In this study, Xpert was performed on the first specimen whilst LPA and sequencing were 
performed on the culture isolate from the second specimen. We did not sequence directly 
from sputum for Part 1 of the study, as the specimen that was used for Xpert testing was 
not available by the time that discordance was detected. It is therefore possible that we 
may have under-called cases of mixed infection which has been described as occurring 
with high frequency in our setting (Warren et al., 2004). Sequencing applied directly to 
sputum may have detected mixed infection with resistant and susceptible strains and this 
would account for more of the discordance between Xpert and LPA. 
Sequencing was not performed on the comparator group for Part 1 of the study due to 
resource limitations. This would have confirmed that there was a mutation present in the 
comparator group, which would be expected to be in the region of the probes determined 
by Xpert and LPA. However, since the probes involved in resistance for both the Xpert 
and the LPA corresponded in every case (e.g. if mutation was in probe E for Xpert, it was 
in WT8 band for LPA), we are of the opinion that the comparator group does represent a 
true resistant group to compare with the false resistant cases. 
A limitation of Part 2 of the study is the fact that we have no supporting clinical outcome 

































The high prevalence of MDR-TB worldwide necessitates the availability of rapid and 
accurate drug susceptibilty testing methods. The test method should not only have a rapid 
turnaround time, be amenable to high throughput and be available at an affordable cost 
but it should also be accurate for detecting resistance in MTB in all settings including high 
burden developing countries. 
Rapid molecular test methods such as GenoType MTBDRplus LPA and Xpert MTB/RIF 
are very good at screening for MDR-TB. However, it is important for the end-user of the 
result to know that neither of these rapid molecular diagnostic methods nor phenotypic 
methods are perfect in predicting MTB drug susceptibility (Rigouts et al., 2013, Van Deun 
et al., 2015, Van Deun et al., 2009). In cases of discordant RIF susceptibility results 
between different diagnostic methods, DNA sequencing, if available, should be performed 
to obtain the predicted resistance result, based on an accurate identification of genotype.  
However, this tool is not routinley available in low resource settings where the burden of 
TB disease is greatest. 
In cases where Xpert is used as a screening tool for MDR-TB it is recommended by the 
WHO that another test method is used to confirm RIFR (WHO, 2011). We recommend, 
that in a case of RIF resistance detected by an Xpert MTB/RIF test that is due to probe 
delay with a Ct max value of between 4.1 and 4.9, double probe delay or with an 
abnormal graph curve, the RIF resistant result should not be released to clinicians. The 
result should be changed to RIF inconclusive and the Xpert test should be repeated on a 
second specimen from the patient. Xpert MTB/RIF parameters (probe Ct values, bacterial 
load, probes involved and graph curves) should be checked before reporting an Xpert 
MTB/RIF RIFR result to clinicians. In a case of Xpert / LPA discordance where no error on 
the part of Xpert is detected, the LPA strip result must be checked thoroughly and 
repeated prior to releasing LPA result. The submission of multiple specimens for repeat 
Xpert and LPA is useful to determine which result is in error, as well as to prove mixed 
infection which can cause discordant results, but comes with additional costs. Specimen 
mix-up could be the cause of discordance and should be ruled out by repeating the LPA 





Mixed MTB infection is not an uncommon cause for discordant rifampicin Xpert / LPA 
results and though it was detected at a low frequency in this study, this may be a due to 
a limitation of the methodology, as it is thought to occur at moderate to high frequency in 
high TB burden setttings (Warren et al., 2004, Shamputa et al., 2006, Folkvardsen et al., 
2013, Zetola et al., 2014). It is difficult to rule out or in mixed infection and depends on 
multiple specimens being submitted (for now; until a better diagnostic is developed and 
proven to be reliable) and that perhaps WGS on direct specimens will assist in 
determining the exact prevalence of it in newly diagnosed TB cases. More studies 
determining its frequency and optimal diagnostic tools that can detect heteroresistance 
accurately are required. 
Arising from this study is a laboratory based guideline that is now used within NHLS TB 
laboratories detailing steps on how to detect possible false RIFR results by Xpert MTB/RIF 
and on how to troubleshoot discordant Xpert RIFR and LPA RIFS results (Appendix A). 
As new tests are implemented and experience is gained with their use in routine 
laboratories, more information becomes available that may be useful to share with other 
laboratories using the same test. The same information may assist manufacturers in 
improving their assays. A new cartridge, Xpert Ultra will be implemented in the near future, 
in South Africa. Ultra promises a lower limit of detection of MTB (15.6 CFU/ml), and 
improved RIF resistance detection (Chakravorty et al., 2017). Hain Lifesciences have 
developed an updated technology for the LPA called the FluoroType MTBDR assay(de 
Vos M, 2017). It is hoped that the discordance for rifampicin between Xpert and LPA is 
minimised once new assays are in routine use, but ongoing monitoring and evaluations 
are important and routine laboratories are best placed to determine this. 
The majority of the miscellanous rpoB mutations that we detected (61.2%) had MICs 
ranging between 0.125 and 1.0 µg/ml which is regarded as low level RIFR resistance that 
would be missed by MGIT DST. A futher 17.4% had MIC ≤0.0625 µg/ml which is regarded 
as RIFS; these would be expected to be correctly called as RIFS by MGIT DST. 
Laboratories that utilize MGIT or other liquid based phenotypic DST would interpret these 
isolates as RIFS at a critical concentration of 1 µg/ml, thus leading to a discordant result 





important to further determine the frequency of these misceallanous rpoB mutations in 
more settings, and to determine the clinical significance of each of them (Sirgel et al., 
2013). 
The LPA is useful in that it can be used to rule out a high level RIFR (“undisputed”) rpoB 
mutation and can indicate a likely disputed rpoB mutation that would be expected to give 
a RIFS result by MGIT DST. Laboratories using the LPA must in conjunction with the end-
user of the result determined whether to add to the report about whether a high level or 
low level RIF resistance mutation has been detected by the LPA. At the present time, the 
LPA package insert states that whenever there is an absent WT band, even in the case 
of an absent MUT band, the RIF result should be reported as resistant. There is no way 
that the end-user knows whether the rpoB mutation detected by the LPA confers high or 
low level RIF resistance. 
In cases where a non-high level RIFR mutation is detected by the genotypic test, and 
where alternative drug options are not available, or are contra-indicated, it may be useful 
to add high dose rifampicin  (Ho et al., 2013) or rifabutin to the drug regimen (Sirgel et al., 
2013). 
A database has been created from the results obtained in this study that lists specific 
rpoB mutations and their corresponding MIC value (Appendix B). This can be used as a 
reference in regional laboratories to provide clinicians with the frequency of particular 
rpoB mutations per LPA pattern detected as well as the likely level of RIF resistance that 
can be expected for each mutation. More studies describing miscellaneous rpoB 
mutations in different regions are required as there seems to be some geographical 
variation in the distribution of the rpoB mutations (Ioerger et al., 2010, Georghiou et al., 
2016). In the future performing MIC testing will be helpful in compiling  individualized 
treatment regimens. 
The question of whether to report the likely rpoB mutation when a disputed, low level RIF 
resistance mutation is expected needs to be answered by clinical studies where patient 
who are infected with MTB harbouring these mutations are followed up for clinical 
outcomes of cure and relapse, in relation to the drug regimen used. The optimal drug 
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6.1 Appendix A 
Guideline for TB laboratories to investigate possible false RIFR by Xpert and discordance with a subsequent 
RIFS by LPA  
1. All RIFR results by Xpert should be checked prior to releasing the result. During Xpert review 
check the Xpert parameters for a possible false RIFR result. 
a. Probe delay where the ∆Ct max value is between 4.1 and 4.9 
• Report RIF inconclusive, repeat Xpert on second specimen 
b. Double probe delay (specifically delayed hybridization of probes D and E) 
• Report RIF inconclusive, repeat Xpert on second specimen 
c. An abnormal graph fluorescence curve  
• Report RIF inconclusive, repeat Xpert on second specimen 
2. If a RIFS result by LPA is reported, but this is discordant with an already-reported Xpert result 
of RIFR 
a. Check the Xpert readout and graph (as point 1 above)  
b. If Very Low MTB bacterial load was detected by Xpert, then it is likely false RIFR by 
Xpert 
c. Note which probe is involved (Ct=0 or delay >4) in the Xpert RIFR result 
• If for example the RIFR result by Xpert was due to probe dropout or probe delay 
of probe D, it is expected that the LPA has an absent rpoB WT7 band. The LPA 
WT7 band may be equal or darker in intensity than the AC band (especially if the 
AC bands of most strips in the batch are very light) but intensity of WT7 should be 
compared to intensity of all the other rpoB WT bands. If it is lighter than the 
others rpoB WT bands it is possible that it should be interpreted as absent rather 
than present (and hence resistant rather than susceptible for RIF) 
d. Check LPA result again and repeat if indicated 
• Obtain the LPA strip if possible. If not possible, obtain a photo of the strip (in a case 
where Genoscan was in use). Look again at the intensity of all the rpoB WT bands. 





made only with the AC band, in some cases of false RIFS results by LPA, the AC band 
is particularly light, and the WT2 / WT7 band in particular is more intense than the 
AC band; however, the WT2/7 band may be lighter than the adjacent rpoB WT 
bands in a case where Xpert has detected resistance due to probe delay / dropout 
in probes A / D respectively 
e. If there is no obvious questionable rpoB WT bands, consider repeating the LPA 
f. Batches of LPA should be checked for any indication of contamination; specimen / 
culture mix up i.e. laboratory contamination# I should be ruled out prior to reporting 
of any results 
3. All previous and current results of a patient should be checked prior to reporting results to 
clinicians; 
a. Actively look for all previous molecular (Xpert and LPA) results on the patient, as well 
as any phenotypic DST results 
b. Examine the probe patterns and graphs of each Xpert and LPA result to make sure no 
technical errors occurred 
c. Multiple specimens / isolates with repeatedly discordant results may be an indication 





4. Repeat testing  
a. If interpretation of all performed tests seems correct according to the probe patterns 
expected, and the Xpert graphs look normal, repeat testing is recommended: 
b. LPA should be repeated as not always possible to repeat Xpert on the same specimen at 
the time of discordance and repeating the Xpert on culture may be considered 
c. If the Xpert parameters indicate likely false RIF resistance, the Xpert should be repeated 
on a second sample that should be submitted (a comment must be added to original 
Xpert report) 
d. If repeat testing gives the same result, further tests may be done, if available  
• Phenotypic DST (MGIT method most commonly available); the limitations of 
particularly liquid based phenotypic should be considered i.e. MGIT DST may miss 
disputed rpoB mutations that confer low level RIF resistance  
e. If the Xpert and LPA results are not altered after all results are checked, the isolate (on 
















6.2 Appendix B 
Table 11:  Relationship between rpoB mutations and MIC values (MGIT 960 EpiCenter) 












≤0.0625 0.125 0.25 0.5 1 >1.0 Total 
L511P 23 27 3 0 0 0 53 
H526N 6 10 3 0 0 0 19 
L533P 0 2 10 12 3 0 27 
D516Y 0 0 10 15 4 1 30 
H526L 0 0 0 1 6 4 11 
S531W 0 0 0 0 0 4 4 
D516F 0 0 0 0 0 5 5 
D516G 1 0 0 0 0 0 1 
Q513P 0 0 0 0 0 3 3 
Q513K 0 0 0 0 0 2 2 
S522L 0 0 0 0 0 2 2 
H526R 0 0 0 0 0 1 1 
S531C 1 0 0 0 0 0 1 
S531F 0 0 0 0 0 1 1 
S531Q 0 0 0 0 0 1 1 
L511P/D549E 0 1 0 0 0 0 1 
D516G/I572M  0 0 0 0 0 1 1 
H526N/S531W 0 0 0 0 0 1 1 
Q510L/D516Y 0 0 0 0 0 1 1 
D516Y/I572M 0 0 0 0 0 1 1 
D516G/L533P 0 0 0 0 0 1 1 
L511P/M515V/V581A 0 0 0 0 1 0 1 
del 518 0 0 0 0 0 1 1 
del517/518 0 0 0 1 0 0 1 
del 514/515 0 0 0 0 0 1 1 
del 514/515/516 0 0 0 0 0 3 3 
del 515/516/517 0 0 0 0 0 1 1 
del 513/514/515 0 0 0 0 0 1 1 
del 515/516/517/518 0 0 0 0 0 1 1 
del 511/512/513/514 0 0 0 0 0 1 1 
Total 31 40 26 29 14 38 178 
MIC = minimum inhibitory concentration, MGIT = mycobacterial growth indicator tube, RIFS = Rifampicin 
susceptible, RIFR = Rifampicin resistant 
